凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
上海医药(601607)公告正文

上海市医药股份有限公司2005年半年度报告

公告日期 2005-08-27
股票简称:上海医药 股票代码:601607

                     上海市医药股份有限公司2005年半年度报告

    目录
    一、重要提示
    二、公司基本情况
    三、股本变动及股东情况
    四、董事、监事和高级管理人员
    五、管理层讨论与分析
    六、重要事项
    七、财务会计报告
    八、备查文件目录
    一、重要提示
    1、本公司董事会及其董事保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
    2、独立董事王巍先生因公出差,委托独立董事冯正权先生代行表决权。
    3、公司半年度财务报告未经审计。
    4、公司董事长钱琎先生、总经理余金琦女士、财务总部部长许薇薇女士声明:保证本半年度报告中财务报告的真实、完整。
    二、公司基本情况(一)公司基本情况简介
    1、公司法定中文名称:上海市医药股份有限公司
    公司英文名称:SHANGHAI PHARMACEUTICAL CO.,LTD
    公司英文名称缩写:SHAPHAR
    2、公司A股上市交易所:上海证券交易所
    公司A股简称:上海医药
    公司A股代码:600849
    3、公司注册地址:上海市浦东新区金桥路1399号
    公司办公地址:上海市浦东新区金桥路1399号
    邮政编码:200129
    公司国际互联网网址:www. shaphar.com.cn
    公司电子信箱:shaphar@shaphar.com.cn
     4、公司法定代表人:钱琎
     5、公司董事会秘书:曹伟荣
    电话:(021)58999999
    传真:(021)58995835
    E-mail:caowr@elong.com
    联系地址:上海市浦东新区金桥路1399号
    6、公司信息披露报纸名称:《上海证券报》、《中国证券报》
    登载公司年度报告的中国证监会指定国际互联网网址:http://www.sse.com.cn 
    公司年度报告备置地点:董事会办公室
    (二)主要财务数据和指标
    1、主要会计数据和财务指标
    单位:元    币种:人民币
主要会计数据                                                   本报告期末
流动资产                                                 5,446,830,017.62
流动负债                                                 4,974,152,693.33
总资产                                                   7,172,405,341.66
股东权益(不含少数股东权益)                             1,815,951,501.95
每股净资产                                                           3.83
调整后的每股净资产                                                   3.53
                                                         报告期(1-6月)
净利润                                                      51,315,602.94
扣除非经常性损益后的净利润                                  39,379,809.38
每股收益                                                             0.11
净资产收益率(%)                                                    2.83
经营活动产生的现金流量净额                                 -43,978,407.34
主要会计数据                                                   上年度期末
流动资产                                                 4,750,536,466.01
流动负债                                                 4,272,673,022.73
总资产                                                   6,464,172,264.12
股东权益(不含少数股东权益)                             1,763,288,884.24
每股净资产                                                           3.72
调整后的每股净资产                                                   3.46
                                                                 上年同期
净利润                                                      88,900,412.63
扣除非经常性损益后的净利润                                  66,442,106.17
每股收益                                                             0.19
净资产收益率(%)                                                    4.89
经营活动产生的现金流量净额                                  -6,915,001.45
                                                         本报告期末比上年
主要会计数据
                                                         度期末增减(%)
流动资产                                                            14.66
流动负债                                                            16.42
总资产                                                              10.96
股东权益(不含少数股东权益)                                         2.99
每股净资产                                                           2.99
调整后的每股净资产                                                   1.91
                                                         本报告期比上年同
                                                             期增减(%)
净利润                                                             -42.28
扣除非经常性损益后的净利润                                         -40.73
每股收益                                                           -43.06
净资产收益率(%)                                        减少2.06个百分点
经营活动产生的现金流量净额                                         535.99
    2、扣除非经常性损益项目和金额
    单位:元     币种:人民币
非经常性损益项目                                                     金额
处置除公司产品外的其他资产产生的损益                        10,877,316.15
各种形式的政府补贴                                           1,491,986.68
短期投资收益                                                   -25,773.94
扣除资产减值准备后的其他各项营业外收入、支出                  -407,735.33
合计                                                        11,935,793.56
    3、按中国证监会发布的《公开发行证券公司信息披露编报规则》第9号的要求计算的净资产收益率及每股收益
    单位:元     币种:人民币
                                             净资产收益率(%)
报告期利润
                                           全面摊薄              加权平均
主营业务利润                                  23.71                 23.71
营业利润                                       4.13                  4.13
净利润                                         2.83                  2.83
扣除非经常性损益后的净利润                     2.17                  2.17
                                                       每股收益
报告期利润
                                           全面摊薄              加权平均
主营业务利润                                   0.91                  0.91
营业利润                                       0.16                  0.16
净利润                                         0.11                  0.11
扣除非经常性损益后的净利润                     0.08                  0.08
    三、股本变动及股东情况
    (一)股本变动情况
    报告期内,公司股份总数及股本结构未发生变化。
    (二)股东情况
    1、报告期末公司股东总数为58,882户。
    2、前十名股东持股情况
    单位:股
                                    报告期内      报告期末持
股东名称(全称)                                                    比例(%)
                                        增减          股数量
上海医药(集团)有限公司                   0     188,248,134        39.69
镇江市技术交流站                        未知       1,873,600         0.40
王洪艳                                     0       1,277,672         0.27
谢勤才                                     0       1,233,363         0.26
中国银行-嘉实服务增值行业证券
                                  -1,092,878       1,158,807         0.24
投资基金
朊小来                                     0       1,148,752         0.24
张雄                                       0       1,070,923         0.23
张和生                                     0         958,109         0.20
中国工商银行-华安上证180指数
                                    +205,528         947,369         0.20
增强型证券投资基金
丁海伟                                     0         919,327         0.19
                                      股份类别
                                                                 股东性质
                                      股份类别       质押或
                                                                 (国有股
股东名称(全称)                        (已流通       冻结情
                                                                 东或外资
                                        或未流           况
                                                                   股东)
                                          通)
上海医药(集团)有限公司                未流通           无      国有股东
镇江市技术交流站                        已流通         未知
王洪艳                                  已流通         未知
谢勤才                                  已流通         未知
中国银行-嘉实服务增值行业证券
                                        已流通         未知
投资基金
朊小来                                  已流通         未知
张雄                                    已流通         未知
张和生                                  已流通         未知
中国工商银行-华安上证180指数
                                        已流通         未知
增强型证券投资基金
丁海伟                                  已流通         未知
    前十名股东关联关系或一致行动的说明
    (1)报告期内,上海医药(集团)有限公司为公司唯一持股5%以上的股东,持股数量188,248,134股,持股比例39.688%,股份性质为国家股,2005年1月28日起股份性质变更为国有法人股。
    (2)报告期内,持股5%以上股东的股份未发生质押、冻结情况。
    (3)公司第一大股东上海医药(集团)有限公司与其余9位股东不存在关联关系,也不属于《上市公司股东持股变动信息披露管理办法》规定的一致行动人;公司未知其余9位股东之间有无关联关系,也未知其余9位股东是否属于《上市公司股东持股变动信息披露管理办法》规定的一致行动人。
    3、前十名流通股股东持股情况
                                                         期末持有流通股的
股东名称
                                                                     数量
镇江市技术交流站                                                1,873,600
王洪艳                                                          1,277,672
谢勤才                                                          1,233,363
中国银行-嘉实服务增值行业证券投资基金                          1,158,807
朊小来                                                          1,148,752
张雄                                                            1,070,923
张和生                                                            958,109
中国工商银行-华安上证180指数增强型证券投资基金                   947,369
丁海伟                                                            919,327
招商银行股份有限公司-长城久泰中信标普300指数证券                 887,894
                                                            种类(A、B、H
股东名称
                                                               股或其它)
镇江市技术交流站                                                      A股
王洪艳                                                                A股
谢勤才                                                                A股
中国银行-嘉实服务增值行业证券投资基金                                A股
朊小来                                                                A股
张雄                                                                  A股
张和生                                                                A股
中国工商银行-华安上证180指数增强型证券投资基金                       A股
丁海伟                                                                A股
招商银行股份有限公司-长城久泰中信标普300指数证券                     A股
    (1)前十名流通股股东关联关系的说明
    未知前十名流通股股东之间存在关联关系或一致行动人的情况
    (2)前十名流通股股东和前十名股东之间关联关系的说明
    未知前十名流通股股东和前十名股东之间的关联关系
    4、控股股东及实际控制人变更情况
    报告期内,公司控股股东及实际控制人没有发生变更。
    四、董事、监事和高级管理人员
    (一)董事、监事和高级管理人员持股变动
    报告期内,公司董事、监事、高级管理人员持股未发生变化。
    (二)新聘或解聘公司董事、监事、高级管理人员的情况
    报告期内,公司副总经理崔志平先生因个人原因辞职。
     五、管理层讨论与分析
    (一)报告期内整体经营情况的讨论与分析
    报告期内,公司以科学发展观为指导,以更强、更精、更专业为方针,以优化资源配置为基础,以进一步提高上海及华东纯销市场份额为重点,积极构筑华东分销网络,铸造一流品牌,实现持续发展。
    报告期内,公司实现主营业务收入60.66亿元,实现主营业务利润4.31亿元,实现利润总额8065.71万元,实现净利润5131.56万元。
    (二)报告期公司经营情况
    1、公司主营业务的范围及其经营情况
    (1)公司主营业务经营情况的说明
    公司经营范围主要是化学原料药、化学药制剂、抗生素、生化药品、生物制品和中成药,以及13大类进出口业务范围内的各项生产经营。
    (2)占报告期主营业务收入或主营业务利润10%以上(含10%)的行业或产品    单位:元     币种:人民币
                                                                     毛利
分行业                            主营业务收入      主营业务成本
                                                                   率(%)
工业                            180,732,947.17    143,077,573.56    26.32
商业                          6,583,984,713.01  6,180,392,617.41     6.53
服务业                              332,716.40
合计                          6,765,050,376.58  6,323,470,190.97     6.98
公司内各业务分部相互
                               -698,901,318.61   -698,901,318.61
抵消
合计                          6,066,149,057.97  5,624,568,872.36     7.85
其中:关联交易                  150,154,502.60    145,649,867.52     3.00
                             主营业             主营业
                           务收入比           务成本比           毛利率比
分行业                     上年同期           上年同期           上年同期
                               增减               增减           增减(%)
                             (%)             (%)
工业                         -62.18             -58.57             -27.47
商业                          19.19              20.11              +0.49
服务业
合计                          12.72              15.16              -1.26
公司内各业务分部相互
抵消
合计                           8.90              11.16              -1.37
其中:关联交易
    (3)主营业务分地区情况表
    单位:元     币种:人民币
分地区                                                       主营业务收入
上海                                                     5,553,777,820.88
浙江                                                       888,766,026.56
安徽                                                        93,768,273.48
山东                                                       213,326,802.93
其他                                                        15,411,452.73
公司内各业务分部相互抵消                                  -698,901,318.61
合计                                                     6,066,149,057.97
                                               主营业务收入比上年同期增减
分地区
                                                                     (%)
上海                                                                14.38
浙江                                                             2,501.28
安徽                                                                46.45
山东                                                                 9.24
其他                                                               -96.34
公司内各业务分部相互抵消
合计                                                                 8.90
    (4)主要控股公司的经营情况及业绩
    单位:万元      币种:人民币
公司名称                                                         经营范围
上海华氏大药房有限公司                                           药品销售
宁波医药股份有限公司                                             药品销售
上海沪中医药有限公司                                             药品销售
上海外高桥医药分销中心有限公司                                   药品销售
公司名称                                                         注册资本
上海华氏大药房有限公司                                               9000
宁波医药股份有限公司                                              5797.77
上海沪中医药有限公司                                              1000.00
上海外高桥医药分销中心有限公司                                    1000.00
公司名称                                                         资产规模
上海华氏大药房有限公司                                     455,096,150.36
宁波医药股份有限公司                                       511,814,270.09
上海沪中医药有限公司                                       239,150,419.12
上海外高桥医药分销中心有限公司                             246,627,857.65
公司名称                                                           净利润
上海华氏大药房有限公司                                       4,864,201.84
宁波医药股份有限公司                                         3,669,889.57
上海沪中医药有限公司                                        10,617,325.15
上海外高桥医药分销中心有限公司                               2,628,833.34
    2、在经营中出现的问题与困难及解决方案
    报告期内,公司面临着药品持续降价和产业竞争更趋激烈的严峻挑战,也面临着市场重组、需求增长和区域联动的重要机遇。公司将积极克服制约企业持续发展的瓶颈,建设有竞争力的华东分销网络,增强品种运作能力,提升增值服务水准,提升竞争能力,努力使公司实现新的增长。
    (三)公司投资情况
    1、募集资金使用情况
    公司于2000年通过配股募集资金60,186万元人民币,已累计使用54,456.15万元人民币,其中本年度已使用700万元人民币,尚未使用5,729.85万元人民币。
    2、承诺项目使用情况
    单位:万元      币种:人民币
承诺项目名称                                                   拟投入金额
医药生物高新科技类项目                                              1,350
医药商业网络建设类项目                                           21,392.5
现代物流配送体系类项目                                              6,000
所属工业改扩建类项目                                               10,161
投资收购或参股医药工业企业类项目                                   10,250
华氏资产经营公司增资扩股项目                                        5,400
补充流动资金                                                      5,632.5
合计                                                               60,186
承诺项目名称                                                 是否变更项目
医药生物高新科技类项目                                           部分变更
医药商业网络建设类项目                                           部分变更
现代物流配送体系类项目                                                 否
所属工业改扩建类项目                                             部分变更
投资收购或参股医药工业企业类项目                                 部分变更
华氏资产经营公司增资扩股项目                                           否
补充流动资金                                                           否
合计                                                                    /
承诺项目名称                                                 实际投入金额
医药生物高新科技类项目                                                650
医药商业网络建设类项目                                           21,051.5
现代物流配送体系类项目                                            2,757.6
所属工业改扩建类项目                                             10,160.5
投资收购或参股医药工业企业类项目                                 9,704.05
华氏资产经营公司增资扩股项目                                        5,400
补充流动资金                                                      5,632.5
合计                                                            54,456.15
承诺项目名称                                             是否符合计划进度
医药生物高新科技类项目                                                 是
医药商业网络建设类项目                                                 是
现代物流配送体系类项目                                                 是
所属工业改扩建类项目                                                   是
投资收购或参股医药工业企业类项目                                       是
华氏资产经营公司增资扩股项目                                           是
补充流动资金                                                           是
合计                                                                    /
    报告期内,各项目实施情况如下:
    (1)医药生物高科技类项目:该项目已实施完毕。
    (2)医药商业网络建设类项目:该项目已实施完毕。
    (3)现代物流配送体系类项目:报告期内,公司以募集资金出资700万元用于医药品仓储改扩建项目。该项目系国债投资和募集资金配套投资项目,预计2005年末竣工。
    (4)所属医药工业改扩建类项目:该项目已实施完毕。
    (5)收购或参股医药工业类项目:该项目部分变更后,新增的合资组建青岛华氏国风医药有限公司项目已实施完毕,新增的合资组建上海医药(古华)药业有限公司项目因合作方情况发生变化未实施。
    (6)剩余募集资金情况:根据项目实施计划进度,除已投资的金额外,其它剩余资金作为流动资金。
    3、非募集资金项目情况
    (1)收购宁波联合集团医药板块三家公司股权
    该项目总投资14258.7万元,报告期内公司出资2518.4万元投资该项目,已完成。
   (2)收购宁波医药股份有限公司部分职工股股权
    该项目总投资422.6万元,报告期内公司出资422.6万元投资该项目,已完成。
    (3)收购上海医药商务网络有限公司股权
    该项目总投资192万元,报告期内公司出资192万元投资该项目,已完成。
    (4)收购上海市长宁医药有限公司股权
    该项目总投资162.4万元,报告期内公司出资162.4万元投资该项目,已完成。
    六、重要事项
    (一)公司治理的情况
    报告期内,公司2004年度股东大会审议通过了《关于修改公司章程的议案》,在原《公司章程》中增加了股东大会分类表决的有关要求及程序,进一步维护了社会公众股的合法权益。
    (二)报告期内实施的利润分配方案执行情况
    报告期内,经公司2004年度股东大会审议通过的2004年度利润分配方案为:以2004年度末总股本474,310,737股为基数,每10股派发现金红利0.80元(含税)。以上利润分配股权登记日为2005年8月18日,除息日为2005年8月19日,该方案已于2005年8月25日实施完毕。
    (三)公司中期不进行利润分配,也不进行资本公积金转增股本
    (四)报告期内诉讼仲裁事项
    2005年4月,公司参股企业上海国际医药贸易有限公司(简称:国际医贸)在与江苏汇麟国际贸易有限公司(简称:江苏汇麟)开展外贸代理业务中,发生了4500多万元货款未按期收回的问题,事后又发现还存在已开未到期信用证8000多万元的情况。国际医贸1997年起在开展外贸进口代理业务中,使用了我司部分信用证额度。
    为此,公司立即终止了国际医贸对我司信用证额度的使用,并会同国际医贸向司法机关提起诉讼保全。2005年8月15日,经上海市第一中级人民法院判决,江苏汇麟应于判决生效之日起十日内偿付本公司货款59,261,567.67元及其利息;其担保人天津保税区汇荣国际贸易有限公司、上海汇麟化工有限公司对上述债务承担连带责任;并应向本公司偿付违约金5,926,156.77元。目前,其余应收款项正由司法机关继续审理和追讨中,并大部分得到了有效的控制。上述判决相应资产已得到保全。
    (五)公司收购及出售资产、吸收合并事项
    1、收购资产情况
    (1)经公司二届十三次董事会审议通过,公司现代医药物流中心项目向普陀区桃浦镇政府及所属企业以每亩37万元的优惠价购置80亩项目用地。因双方约定条件变化,经公司二届临时董事会审议通过,双方同意现代医药物流中心项目用地转让价格调整为每亩80万元,我司向桃浦镇政府所属企业上海未来岛投资置业有限公司支付土地差价3440万元,现已实施完毕。
    (2)为推进物流项目合资,经公司二届三十九次董事会审议同意,公司与桃浦镇政府及所属企业协商、签约,将现代物流中心项目用地款和配套补偿费除原款外,调整为8400万元。现因合资未果,经公司董事会审议同意,双方决定终止协议。
    (3) 2005年5月,公司控股企业上海华氏资产经营有限公司投资5760万元购置上海康臻房地产有限公司开发建设的青浦翡翠国际花苑7200平方米商品房。
    2、出售资产情况
    (1)经公司二届三十九次董事会审议通过,公司拟将川桥路1065号土地出让给上海未来岛投资置业有限公司。现因权证转移和土地使用权年限的原因无法实施,公司董事会决定撤消原决议。现双方已签署该土地转让的终止协议,项目已终止实施。
    (2)经公司二届四十一次董事会审议通过,公司以958万元向上海神驰房地产开发经营有限公司转让宁波路100号和120弄2号房地产的使用权、以2760万元向上海英达莱置业有限公司转让愚园路108号房地产、以282万元向上海英达方物业有限公司转让陕西北路470弄26~27号房地产。
    (3)公司真南路仓库2003年被列入普陀区市政动迁范围,经公司二届临时董事会审议通过,双方商定,动迁方普陀区桃浦镇所属企业真阳房产公司先后分两次向我司支付动迁补偿费,补偿费总额为6093万元,现已实施完毕。
    (六)报告期内公司重大关联交易事项
    本报告期公司无重大关联交易事项。
    (七)重大合同及其履行情况
    1、托管情况
    公司控股子公司上海华氏大药房有限公司自2003年1月起由上海中西药业股份有限公司托管至今。
    2、承包情况
    报告期内,公司无承包事项。
    3、租赁情况
    报告期内,公司无租赁事项。
    4、担保情况
    单位:元     币种:人民币
                   公司对外担保情况(不包括对控股子公司的担保)
                      发生日期
担保对象名称        (协议签署          担保金额                 担保类型
                          日)
上海市糖业烟
酒(集团)有        2004-12-17                                   连带责任
                                     158,000,000
                                                                     担保
限公司
同济大学附属                                                     连带责任
                      2002-3-5        14,774,000
同济医院                                                             担保
                 公司对外担保情况(不包括对控股子公司的担保)
                                                                 是否为关
                                             是否履              联方担保
担保对象名称               担保期
                                             行完毕                (是或
                                                                     否)
上海市糖业烟
酒(集团)有
                         2006-3-1                否                    否
限公司
同济大学附属
                        2009-10-5                否                    否
同济医院
报告期内担保发生额合计                                     100,000,000.00
报告期末担保余额合计                                       172,774,000.00
                        公司对控股子公司的担保情况
报告期内对控股子公司担保发生额合计                          94,400,000.00
报告期末对控股子公司担保余额合计                           206,600,000.00
        公司担保总额情况(包括对控股子公司的担保)
担保总额                                                   379,374,000.00
担保总额占公司净资产的比例                                         20.89%
                            公司违规担保情况
为公司持股50%以下的其他关联方提供担保的金额                24,000,000.00
直接或间接为资产负债率超过70%的被担保对象提供的债务
                                                           165,500,000.00
担保金额
担保总额是否超过净资产的50%(是或否)                                 否
违规担保金额                                               189,500,000.00
    5、委托理财情况
    ①2004年3月,公司与申银万国证券股份有限公司签订金额为1亿元的资产管理协议,至2004年12月31日,该笔资金已全部收回。
    ②2004年1月,公司控股企业上海华氏资产经营有限公司与中国银河证券有限公司上海张扬路营业部签订金额为5000万元期限至2004年底的资产管理协议。2005年4月,银河证券上海张扬路营业部对该笔业务及资金的处置提出了初步意见;2005年7月,该营业部告知,因银河证券正在注资重组,该笔业务及资金将在重组后予以解决。
    6、其他重大合同
    报告期内,公司无其他重大合同。
    (八)公司或持有5%以上股东对公开披露承诺事项的履行情况
    报告期内,公司控股股东上海医药(集团)有限公司正按承诺积极推进解决上市公司资金占用问题。
    (九)公司、董事会、董事受处罚及整改情况
    报告期内,公司、公司董事会及董事均未受中国证监会的稽查、行政处罚、通报批评及证券交易所的公开谴责。
    (十)其它重大事项
    报告期内,公司无其他重大事项。
    (十一)信息披露索引
                                                       刊载的报刊名称及版
事项
                                                                       面
                                                          上海证券报3版、
国家股变更为国有法人股的提示性公告
                                                          中国证券报B33版
                                                          上海证券报C叠、
二届三十五次董事会决议公告
                                                           中国证券报22版
                                                          上海证券报C版、
王震董事、王晓玲监事辞职的提示性公告
                                                          中国证券报C38版
                                                          上海证券报C版、
二届三十六次董事会决议公告
                                                          中国证券报C20版
                                                          上海证券报C版、
二届十五次监事会决议公告
                                                          中国证券报C20版
                                                          上海证券报C版、
2004年年报摘要
                                                          中国证券报C20版
                                                          上海证券报9版、
2005年第一季度报告
                                                          中国证券报C66版
二届三十八次董事会决议暨召开2004年度                      上海证券报C版、
股东大会公告                                              中国证券报C23版
                                                          上海证券报C版、
2004年度股东大会召开地点的公告
                                                          中国证券报C04版
事项                                                             刊载日期
国家股变更为国有法人股的提示性公告                           2005-01-29
二届三十五次董事会决议公告                                   2005-02-02
王震董事、王晓玲监事辞职的提示性公告                         2005-04-21
二届三十六次董事会决议公告                                   2005-04-27
二届十五次监事会决议公告                                     2005-04-27
2004年年报摘要                                               2005-04-27
2005年第一季度报告                                           2004-04-30
二届三十八次董事会决议暨召开2004年度
                                                             2005-05-31
股东大会公告
2004年度股东大会召开地点的公告                               2005-06-23
                                                           刊载的互联网网
事项
                                                             站及检索路径
国家股变更为国有法人股的提示性公告                         www.sse.com.cn
二届三十五次董事会决议公告                                 www.sse.com.cn
王震董事、王晓玲监事辞职的提示性公告                       www.sse.com.cn
二届三十六次董事会决议公告                                 www.sse.com.cn
二届十五次监事会决议公告                                   www.sse.com.cn
2004年年报摘要                                             www.sse.com.cn
2005年第一季度报告                                         www.sse.com.cn
二届三十八次董事会决议暨召开2004年度
                                                           www.sse.com.cn
股东大会公告
2004年度股东大会召开地点的公告                             www.sse.com.cn
    七、财务会计报告(未经审计)
     (一)财务报表(附后)
    (二)会计报表附注(附后)
    八、备查文件目录
    上海市医药股份有限公司
    2005年8月25日
    上海市医药股份有限公司
    2005年上半年会计报表附注
    一、公司简介:
    上海市医药股份有限公司(以下简称公司)是由上海医药(集团)有限公司以原所属的全资子公司上海市医药有限公司、上海医药工业销售有限公司和上海天平制药厂的优质资产等额置换了上海四药股份有限公司的全部资产而组建的,于1998年9月9日复牌上市。公司注册地为:浦东金桥路1399号。企业法人营业执照注册号为:3100001002799。股票代码为:600849。公司行业类别:医药类。公司经营范围:化学原料药,化学药制剂,抗生素,生化药品生物制品,中成药(含参茸银茸),医疗器械,制药设备,化学危险物品,食品,日用百货,商务咨询及上述经营范围内的咨询服务,自营和代理内销商品范围内的进出口商品及相关技术的进出口业务,经营进料加工和“三来一补”业务,经营对销贸易和转口贸易。
    二、公司采用的主要会计政策、会计估计和合并会计报表的编制方法
    (一)会计制度
    执行企业会计准则、《企业会计制度》及其有关的补充规定。
    (二)会计年度
    公历1月1日至12月31日止。
    (三)记帐本位币
    采用人民币为记帐本位币。
    (四)记帐基础和计价原则
    以权责发生制为记帐基础,以历史成本为计价原则。
    (五)外币业务核算方法
    外币业务按发生时的中国人民银行公布的人民币市场汇价作为折算汇率,折合成人民币记帐,年末外币帐户余额按年末市场汇价(中间价)折合成人民币金额进行调整。
外币专门借款帐户年末折算差额,在所购建固定资产达到预定可使用状态前的特定时间段内,按规定予以资本化,计入在建工程成本,其余的外币帐户折算差额均计入财务费用。不同货币兑换形成的折算差额,均计入财务费用。
    (六)外币会计报表的折算方法
    按照财政部财会字(1995)11号《关于印发<合并会计报表暂行规定>的通知》,除所有者权益类项目(不含未分配利润项目)以发生时的市场汇价(中间价)折算为人民币外,资产、负债、损益类项目均以合并会计报表决算日的市场汇价(中间价)折算为人民币。外币报表折算差额在合并资产负债表中单独列示。
    (七)现金等价物的确定标准
    在编制现金流量表时,将同时具备期限短(从购买日起,三个月到期)、流动性强、易于转换为已知现金、价值变动风险很小四个条件的投资,确定为现金等价物。
    (八)短期投资核算方法
    1、取得的计价方法
    取得投资时按实际支付的价款(扣除已宣告未领取的现金股利或已到期未领取的债券利息)、相关税费计价。债务重组取得债务人用以抵债的短期投资,以应收债权的帐面价值为基础确定其入帐价值;非货币性交易换入的短期投资,以换出资产的帐面价值为基础确定其入帐价值。
    2、短期投资跌价准备的计提
    中期末及年末,按成本与收盘价孰低提取或调整短期投资跌价准备。按投资类别计算并确定计提的跌价损失准备。如某项短期投资占整个短期投资10%以上,则按单项投资为基础计提跌价损失准备。
    3、短期投资收益的确认
    短期投资待处置时确认投资收益。在持有期间分得的现金股利和利息,冲减投资成本或相关应收项目。
    (九)坏帐核算方法
    1、坏帐的确认标准
    对因债务人撤销、破产,依照法律清偿程序后确实无法收回的应收款项;因债务人死亡,既无遗产可清偿,又无义务承担人,确实无法收回的应收款项;因债务人逾期未履行偿债义务并有确凿证据表明,确实无法收回的应收款项,按照公司管理权限批准核销。
    2、坏帐损失的核算方法
    采用备抵法核算,按账龄分析法并结合个别认定法估算坏帐损失。
    3、坏帐准备的计提方法和计提比例
    根据期末应收款项余额的账龄按下列比例计提坏账准备:
账龄                                                             计提比例
1年以内                                                              0.5%
1-2年                                                                10%
2-3年                                                                20%
3年以上                                                               50%
    (十)存货核算方法
    1、存货分类为
    存货的分类为:原材料、在产品、产成品、库存商品、商品采购、包装物、低值易耗品。
    2、取得和发出的计价方法
    按实际成本计价,购入并已验收入库的原材料按实际成本入账,发出原材料的成本采用加权平均法核算;入库产品和商品按实际成本核算;发出产成品和商品采用加权平均法核算。
    债务重组取得债务人用以抵债的存货,以应收债权的帐面价值为基础确定其入帐价值;非货币性交易换入的存货以换出资产的帐面价值为基础确定其入帐价值。
    3、低值易耗品的摊销方法
    低值易耗品采用一次摊销法。
    4、存货的盘存制度
    采用永续盘存制。
    5、存货跌价准备的计提方法
    中期末及年末,对存货进行全面清查后,按存货的成本与可变现净值孰低提取或调整存货跌价准备。
    存货跌价准备按单个存货项目计提。
    (十一)长期投资核算方法
    1、取得的计价方法
    长期投资取得时以初始投资成本计价,包括相关的税金、手续费等。债务重组取得债务人用以抵债的股权投资,以应收债权的帐面价值为基础确定其入帐价值;非货币性交易换入的股权投资,以换出资产的帐面价值为基础确定其入帐价值。
    2、长期股权投资的核算方法
    对被投资单位无控制、无共同控制且无重大影响的,采用成本法核算;对被投资单位能实施控制、共同控制或重大影响的,采用权益法核算。
    按权益法核算长期股权投资时,初始投资成本高于应享有被投资单位净资产份额所确认的股权投资差额,若合同规定投资期限的按投资期限平均摊销;若合同未规定投资期限的按10年平均摊销。初始投资成本低于应享有被投资单位净资产份额的差额,计入资本公积(股权投资准备)。2003年以前发生的股权投资差额贷差仍按原规定摊销。再次投资发生的股权投资差额按财会[2004]3号文处理。
    3、长期债权投资的核算方法
    中期末及年末,按合同规定利率或债券票面利率计提利息,并同时按直线法摊销债券投资溢价或折价。
    如果计提的利息到期不能收回,停止计息并冲回原已计提的利息。
    4、长期投资减值准备的计提
    中期末及年末,按预计可收回金额低于长期投资帐面价值的差额,计提长期投资减值准备。自2004年起计提长期投资减值准备时对以前年度已发生的股权投资差额按财会(2004)3号文处理。
    长期投资减值准备按个别投资项目计算确定。
    (十二)委托贷款核算方法
    企业对委托金融机构贷出的款项,按实际委托的贷款金额入帐。年末,按照委托贷款合同规定的利率计提应收利息。如果计提的利息到期不能收回,则停止计息并冲回原已计提的利息。
    中期末及年末,对委托贷款可收回金额低于贷款本金的差额,计提委托贷款减值准备。
    (十三)固定资产计价和折旧方法
    1、固定资产标准:
    指为生产商品、提供劳务、出租或经营管理而持有的并且使用期限超过一年、单位价值较高的有形资产。
    2、固定资产的分类:
    房屋及建筑物、专用设备、通用设备、运输设备、其他设备、固定资产装修、经营租入固定资产改良等。
    3、固定资产的取得计价:
    一般遵循实际成本计价原则计价。
    债务重组取得债务人用以抵债的固定资产,以应收债权的帐面价值为基础确定其入帐价值;非货币性交易换入的固定资产,以换出资产的帐面价值为基础确定其入帐价值。
    融资租入的固定资产,按租赁开始日租赁资产的原帐面价值与最低租赁付款额的现值两者中较低者作为入帐价值,如果融资租赁资产占企业资产总额等于或小于30%的,则按最低租赁付款额作为入帐值。
    4、固定资产折旧采用年限平均法分类计提。根据固定资产类别、预计使用年限和预计净残值率确定折旧率。
固定资产类别                                                 预计使用年限
房屋及建筑物                                                      25-35年
通用设备                                                           5-10年
专用设备                                                           6-18年
运输设备                                                           8-14年
固定资产类别                                                     净残值率
房屋及建筑物                                                          4%
通用设备                                                              4%
专用设备                                                              4%
运输设备                                                              4%
固定资产类别                                                     年折旧率
房屋及建筑物                                                  3.84%-2.74%
通用设备                                                       19.2%-9.6%
专用设备                                                        16%-5.33%
运输设备                                                        12%-6.86%
    符合资本化条件的固定资产装修费用,在两次装修期间与固定资产尚可使用年限两者中较短的期间内,采用年限平均法单独计提折旧;经营租赁方式租入的固定资产改良支出,在剩余租赁期与租赁资产尚可使用年限两者中较短的期间内,采用年限平均法单独计提折旧。
    融资租赁方式租入的固定资产,能合理确定租赁期届满时将会取得租赁资产所有权的,在租赁资产尚可使用年限内计提折旧;无法合理确定租赁期届满时能够取得租赁资产所有权的,在租赁期与租赁资产尚可使用年限两者中较短的期间内计提折旧。融资租赁方式租入的固定资产发生的符合资本化条件的装修费用,在两次装修期间、剩余租赁期与固定资产尚可使用年限三者中较短的期间内,采用年限平均法单独计提折旧。
    5、固定资产减值准备的计提:
    中期末及年末,对由于市价持续下跌、技术陈旧、实体损坏、长期闲置等原因导致其可收回金额低于帐面价值的,按预计可收回金额低于其帐面价值的差额,计提固定资产减值准备。
    固定资产减值准备按单项资产计提。
    (十四)在建工程核算方法
    1、取得的计价方法
    以立项项目分类核算工程发生的实际成本,当所建工程项目达到预定可使用状态时,转入固定资产核算,尚未办理竣工决算的,按估计价值转帐,待办理竣工决算手续后再作调整。
    2、在建工程减值准备的计提
    中期末及年末,对于长期停建并预计在未来三年内不会重新开工的在建工程,或在性能、技术上已落后且给企业带来经济利益具有很大不确定性的在建工程,计提在建工程减值准备。
    在建工程减值准备按单项工程计提。
    (十五)无形资产核算方法
    1、取得的计价方法
    按取得时的实际成本入帐。
    债务重组取得债务人用以抵债的无形资产,按应收债权的帐面价值为基础确定其入帐价值;非货币性交易换入的无形资产,按换出资产的帐面价值为基础确定其入帐价值。
    2、摊销方法
    采用直线法。相关合同与法律两者中只有一方规定受益年限或有效年限的,按不超过规定年数的期限平均摊销;两者均规定年限的按孰低者平均摊销;两者均未规定年限的按不超过十年的期限平均摊销。
    3、无形资产减值准备的计提
    中期末及年末,对于因被其他新技术替代、市价大幅下跌而导致创利能力受到重大不利影响或下跌价值预期不会恢复的无形资产,按预计可收回金额低于其帐面价值的差额,计提无形资产减值准备。
    无形资产减值准备按单项资产计提。
    (十六)长期待摊费用摊销方法
    1、开办费转销方法
    在开始生产经营的当月一次计入损益。
    2、其他长期待摊费用摊销方法
    在受益期内平均摊销,其中:
    预付经营租入固定资产的租金,按租赁合同规定的期限平均摊销。
    (十七)借款费用
    1、借款费用资本化的确认原则
    专门借款的辅助费用在所购建资产达到预定可使用状态前,予以资本化,若金额较小则直接计入当期损益。
    专门借款的利息、溢折价摊销、汇兑差额开始资本化应同时满足以下三个条件:资产支出已经发生、借款费用已经发生、为使资产达到预定可使用状态所必要的购建活动已经开始。
    当购建资产项目发生非正常中断且连续三个月或以上时,借款费用暂停资本化。当购建资产项目达到预定可使用状态后,借款费用停止资本化。
    当购建资产中部分项目分别完工且可单独使用时,该部分资产借款费用停止资本化。
    普通借款的借款费用和不符合资本化规定的专门借款的借款费用,均计入发生当期损益。
    2、借款费用资本化期间
    按季度计算借款费用资本化金额。
    3、专门借款的借款费用资本化金额的确定方法
    每一会计期间利息资本化的金额=至当年末止购建固定资产累计支出加权平均数 借款加权平均利率。
    允许资本化的辅助费用、汇兑差额按实际发生额直接资本化。
    (十八)预计负债
    与或有事项相关的义务同时符合以下条件时,公司将其列为预计负债:    1、该义务是企业承担的现时义务;
    2、该义务履行很可能导致经济利益流出企业;
    3、该义务金额可以可靠地计量。
    (十九)收入确认原则
    1、销售商品
    公司已将商品所有权上的重要风险和报酬转移给买方;公司不再对该商品实施继续管理权和实际控制权;与交易相关的经济利益能够流入企业;相关的收入和成本能可靠地计量时,确认营业收入实现。
    2、提供劳务
    在同一年度内开始并完成,在劳务已经提供,收到价款或取得收取价款的依据时,确认劳务收入的实现;如劳务的开始和完成分属不同的会计年度,在提供劳务交易的结果能够可靠估计的情况下,在资产负债表日按完工百分比法确认相关的劳务收入。
    3、让渡资产使用权
    与交易相关的经济利益能够流入企业,收入的金额能可靠地计量时,按合同或协议规定确认为收入。
    (二十)所得税的会计处理方法
    采用应付税款法。
    (二十一)合并会计报表的编制方法
    1、合并会计报表按照《合并会计报表暂行规定》及有关文件,以母公司和纳入合并范围的子公司的个别会计报表以及其他资料为依据进行编制。但对行业特殊及子公司规模较小,符合财政部财会二字(1996)2号《关于合并会计报表合并范围请示的复函》文件的规定,则不予合并。合并时对内部权益性投资与子公司所有者权益、内部投资收益与子公司利润分配、内部交易事项、内部债权债务进行抵销,对合并盈余公积进行调整。
    2、母公司与子公司采用的会计政策和会计处理方法无重大差异。
    三、税项
    (一)公司主要税种和税率为
税种                                                                 税率
增值税                                                           17%、13%
营业税                                                               3-5%
所得税                                                            15%-33%
    (二)税负减免:
    1、子公司上海禾丰制药有限公司根据上海市税务局对外税务分局沪税上分(1999)78号,自1999年4月起按浦东新区生产企业减按15%缴纳所得税。
    2、子公司上海通用药业股份有限公司根据税务局批准享受高新技术减免所得税优惠政策,本年度减按15%缴纳所得税。
    3、子公司上海浦东华氏医药有限公司自2003年3月起享受浦东新区内资企业所得税优惠政策,减按15%缴纳所得税。
    四、控股子公司及合营企业
    (一)公司所控制的所有子公司、合营企业情况及其合并范围(单位:人民币):被投资单位全称                   注册资本(万元)                经营范围
上海华氏制药有限公
                                        12,559.29                药品制造

宁波亚太生物技术有
                                         4,378.80                药品制造
限公司
上海天平实业公司                            50.00                    贸易
上海天平制药厂保健
                                            35.10                药品制造
食品分厂
上海青平药业有限公
                                           600.00                药品制造

上海金龟华超医药有
                                           300.00                药品销售
限公司
上海华氏大药房有限
                                         9,000.00                药品销售
公司
上海华氏大药房配送
                                           500.00                药品销售
中心有限公司
上海华氏杨浦大药房
                                           100.00                    零售
有限公司
上海华氏武夷大药房
                                           100.00                药品销售
有限公司
嘉兴华氏大药房兰台
                                           900.00                药品销售
零售连锁有限公司
上海华氏虹口大药房
                                           100.00                药品销售
有限公司
上海华氏全新大药房                         100.00                药品销售
有限公司
贵州省华氏大药房延
                                         1,000.00                药品销售
安连锁有限公司
上海市医药股份有限
公司黄山华氏有限公                         300.00                药品销售

安徽省六安华氏大药
                                           150.00                药品销售
房有限公司
南通华氏康乐大药房
                                         1,200.00                药品销售
有限公司
上海华氏资产经营有
                                        11,000.00                    投资
限公司
上海罗达医药有限公
                                           500.00                药品销售

上海沪中医药有限公
                                         1,000.00                药品销售

上海华氏医药高科技
                                           500.00            生物医药研发
实业发展有限公司
上海福达制药有限公
                                         2,880.56                药品制造

上海思富医药有限公
                                         1,200.00                药品销售

上海华仁医药有限公
                                         2,000.00                药品销售

上海大东化学试剂供
                                            10.22                药品销售
应站
上海华臣商场有限公
                                           200.07                药品销售

上海华氏西部大药房
                                           500.00                药品销售
有限公司
上海禾丰制药有限公
                                      USD1,000.00                药品制造

上海瑞金药房                               100.00                药品销售
上海华氏医药储运有
                                           500.00                    运输
限公司
香港思富有限公司                           600.00                药品销售
上海市医药股份有限
                                           450.00                药品销售
公司安庆公司
上海市医药股份有限
                                            85.00                药品销售
公司池州华氏公司
北京市申药产品经销
                                           300.00                药品销售
中心
上海金山医药药材有
                                         1,000.00                药品销售
限公司
上海金石医药药材有
                                           200.00                药品销售
限公司
上海华氏健民药业有
                                           500.00                药品销售
限公司
上海上医新特药商店                          60.00                药品销售
上海华因医药有限公
                                         1,000.00                药品销售

安徽华氏医药有限公
                                           321.00                药品销售

上海医涵药业有限公
                                           500.00                药品销售

上海华氏经济发展有                         500.00                    贸易
限公司
上海外高桥医药分销
                                         1,000.00                药品销售
中心有限公司
江西南华医药有限公
                                        18,000.00                药品销售

江西黄庆仁栈华氏大
                                         1,000.00                药品销售
药房有限公司
江西华康药业有限公
                                         50万美元                药品销售

上海制药(苏丹)有限
                                        USD220.00                药品销售
公司
上海华嘉医药有限公
                                           500.00                药品销售

上海医药嘉定药业有
                                         1,000.00                药品销售
限公司
上海浦东华氏医药有
                                           500.00                药品销售
限公司
上海华天广告有限公
                                           100.00                  广告业

上海市一大药房有限
                                           110.00                药品销售
公司
上海健尔药房有限公
                                           100.00                药品销售

上海闵行药材医药有
                                           800.00                药品销售
限公司
青岛华氏国风医药有
                                         4,600.00                药品销售
限责任公司
杭州华氏医药有限公
                                         1,281.86                药品销售

福建华氏康源医药有
                                         1,000.00                药品销售
限公司
宁波医药股份有限公
                                         5,797.77                药品销售

宁波四明大药房有限
                                         2,380.00                药品销售
责任公司
上海通用药业股份有
                                         4,000.00                药品制造
限公司
                                      母公司实际               母公司控股
被投资单位全称
                                          投资额               比例(%)
上海华氏制药有限公
                                       12,559.29                    90.00

宁波亚太生物技术有
                                             ---                      ---
限公司
上海天平实业公司                             ---                      ---
上海天平制药厂保健
                                             ---                      ---
食品分厂
上海青平药业有限公
                                             ---                      ---

上海金龟华超医药有
                                          300.00                   100.00
限公司
上海华氏大药房有限
                                        8,100.00                    90.00
公司
上海华氏大药房配送
                                             ---                      ---
中心有限公司
上海华氏杨浦大药房
                                             ---                      ---
有限公司
上海华氏武夷大药房
                                             ---                      ---
有限公司
嘉兴华氏大药房兰台
                                             ---                      ---
零售连锁有限公司
上海华氏虹口大药房
                                             ---                      ---
有限公司
上海华氏全新大药房                           ---                      ---
有限公司
贵州省华氏大药房延
                                             ---                      ---
安连锁有限公司
上海市医药股份有限
公司黄山华氏有限公                           ---                      ---

安徽省六安华氏大药
                                             ---                      ---
房有限公司
南通华氏康乐大药房
                                             ---                      ---
有限公司
上海华氏资产经营有
                                        9,900.00                    90.00
限公司
上海罗达医药有限公
                                          137.24                    20.00

上海沪中医药有限公
                                        1,000.00                   100.00

上海华氏医药高科技
                                          500.00                   100.00
实业发展有限公司
上海福达制药有限公
                                        2,016.39                    70.00

上海思富医药有限公
                                          720.00                    60.00

上海华仁医药有限公
                                        1,200.00                    60.00

上海大东化学试剂供
                                           10.22                   100.00
应站
上海华臣商场有限公
                                          200.07                   100.00

上海华氏西部大药房
                                             ---                      ---
有限公司
上海禾丰制药有限公
                                        2,893.40                    50.00

上海瑞金药房                              100.00                   100.00
上海华氏医药储运有
                                          448.86                    90.00
限公司
香港思富有限公司                          600.00                    99.98
上海市医药股份有限
                                          318.00                    60.00
公司安庆公司
上海市医药股份有限
                                           46.75                    55.00
公司池州华氏公司
北京市申药产品经销
                                          153.00                    51.00
中心
上海金山医药药材有
                                          510.00                    51.00
限公司
上海金石医药药材有
                                          102.00                    51.00
限公司
上海华氏健民药业有
                                          334.77                    65.00
限公司
上海上医新特药商店                         60.00                   100.00
上海华因医药有限公
                                          900.00                    90.00

安徽华氏医药有限公
                                          215.00                    67.00

上海医涵药业有限公
                                          500.00                   100.00

上海华氏经济发展有                        500.00                   100.00
限公司
上海外高桥医药分销
                                          650.00                    65.00
中心有限公司
江西南华医药有限公
                                        9,000.00                    50.00

江西黄庆仁栈华氏大
                                          950.00                    95.00
药房有限公司
江西华康药业有限公
                                         130.065                    64.25

上海制药(苏丹)有限
                                          904.30                    55.00
公司
上海华嘉医药有限公
                                          420.00                    84.00

上海医药嘉定药业有
                                          510.00                    51.00
限公司
上海浦东华氏医药有
                                          450.00                    90.00
限公司
上海华天广告有限公
                                           40.00                    40.00

上海市一大药房有限
                                           55.00                    50.00
公司
上海健尔药房有限公
                                           50.00                    50.00

上海闵行药材医药有
                                          560.00                    70.00
限公司
青岛华氏国风医药有
                                        3,800.00                    65.22
限责任公司
杭州华氏医药有限公
                                        1,083.38                    81.00

福建华氏康源医药有
                                        1,919.61                    60.00
限公司
宁波医药股份有限公
                                        9,623.62                    51.05

宁波四明大药房有限
                                        2,199.00                    64.29
责任公司
上海通用药业股份有
                                        1,600.00                    40.00
限公司
                                 合并范围内控       是否
被投资单位全称                                                       备注
                                 股比例(%)       合并
上海华氏制药有限公
                                       100.00         是

宁波亚太生物技术有
                                        89.03         是
限公司
上海天平实业公司                       100.00         否
上海天平制药厂保健
                                        60.00         否
食品分厂
上海青平药业有限公
                                        39.00         否

上海金龟华超医药有
                                       100.00         是
限公司
上海华氏大药房有限
                                       100.00         是
公司
上海华氏大药房配送
                                       100.00         是
中心有限公司
上海华氏杨浦大药房
                                        90.00         是
有限公司
上海华氏武夷大药房
                                       100.00         是
有限公司
嘉兴华氏大药房兰台                                               具有实质
                                        50.00         是
零售连锁有限公司                                                   控制权
上海华氏虹口大药房
                                       100.00         是
有限公司
上海华氏全新大药房                     100.00         是
有限公司
贵州省华氏大药房延
                                        51.00         是
安连锁有限公司
上海市医药股份有限
公司黄山华氏有限公                      64.17         是

安徽省六安华氏大药
                                        53.33         是
房有限公司
南通华氏康乐大药房
                                        82.08         是
有限公司
上海华氏资产经营有
                                       100.00         是
限公司
上海罗达医药有限公
                                        20.00         否

上海沪中医药有限公
                                       100.00         是

上海华氏医药高科技
                                       100.00         是
实业发展有限公司
上海福达制药有限公
                                        70.00         是

上海思富医药有限公
                                        60.00         是

上海华仁医药有限公
                                        60.00         是

上海大东化学试剂供
                                       100.00         是
应站
上海华臣商场有限公
                                       100.00         是

上海华氏西部大药房
                                       100.00         是
有限公司
上海禾丰制药有限公                                               具有实质
                                        50.00         是
司                                                                 控制权
上海瑞金药房                           100.00         是
上海华氏医药储运有
                                       100.00         否
限公司
香港思富有限公司                        99.98         否
上海市医药股份有限
                                        60.00         是
公司安庆公司
上海市医药股份有限
                                        55.00         否
公司池州华氏公司
北京市申药产品经销
                                        51.00         否
中心
上海金山医药药材有
                                        51.00         否
限公司
上海金石医药药材有
                                        51.00         是
限公司
上海华氏健民药业有
                                        65.00         否
限公司
上海上医新特药商店                     100.00         是
上海华因医药有限公
                                       100.00         是

安徽华氏医药有限公
                                        67.00         否

上海医涵药业有限公
                                       100.00         否

上海华氏经济发展有                     100.00         否
限公司
上海外高桥医药分销
                                        65.00         是
中心有限公司
江西南华医药有限公
                                        50.00         否

江西黄庆仁栈华氏大
                                        95.00         否
药房有限公司
江西华康药业有限公
                                        64.25         否

上海制药(苏丹)有限
                                        55.00         否
公司
上海华嘉医药有限公
                                        90.00         是

上海医药嘉定药业有
                                        51.00         是
限公司
上海浦东华氏医药有
                                        90.00         是
限公司
上海华天广告有限公
                                       100.00         否

上海市一大药房有限
                                        50.00         否
公司
上海健尔药房有限公
                                        50.00         否

上海闵行药材医药有
                                        70.00         是
限公司
青岛华氏国风医药有
                                        65.22         是
限责任公司
杭州华氏医药有限公
                                        81.00         是

福建华氏康源医药有
                                        60.00         是
限公司
宁波医药股份有限公
                                        51.05         是

宁波四明大药房有限
                                        64.29         是
责任公司
上海通用药业股份有                                               具有实质
                                        40.00         是
限公司                                                             控制权
    (二)未纳入合并会计报表范围的子公司:
    1、本年度未纳入合并会计报表范围的子公司共一十三家,详见附注四(一)。该一十三家子公司规模较小,符合财政部财会二字(1996)2号《关于合并会计报表合并范围请示的复函》文件的规定,不予合并。
    2、对财务状况及经营成果的影响:
    未纳入合并会计报表范围的子公司加总的资产总额为252,114,842.28元,占母、子公司资产总额的3.52%;销售收入为166,391,051.77元,占母、子公司收入总额的2.74%;净利润144,020.28元,占母公司净利润的0.28%。对未纳入合并会计报表范围的子公司净利润母公司已按权益法核算,计入投资收益39,800.63元。
    (三)纳入合并报表范围但母公司持股比例未达到50%以上的子公司及其原因:    1、公司对上海通用药业股份有限公司(详见附注四(一)),因公司对其实质性控制所以纳入合并报表范围。
    2、公司对上海禾丰制药有限公司、嘉兴华氏大药房兰台零售连锁有限公司的持股比例均为50%,因公司对其实质性控制,选用完全合并法。
    (四)本年度合并报表范围的变更情况:
    1、与上年相比本年新增合并单位三家,原因为:
    (1)宁波医药股份有限公司:本年新增投资,纳入合并范围;
    (2)宁波四明大药房有限公司:本期新增投资,纳入合并范围;
    (3)宁波亚太生物科技有限公司:本期新增投资,纳入合并范围;
    2、本年减少合并单位四家,原因为:
    (1)江西南华医药有限公司:持股比例为50%,已无实质性控制,不纳入合并范围。
    (2)上海罗达医药有限公司:持股比例为20%,不再有重大控制力,不纳入合并范围。
    (3)上海青平药业有限公司:持股比例为39%,已无实质性控制,不纳入合并范围。
    (4)上海医疗器械(集团)有限公司:持股比例为50%,因股权转让,不纳入合并范围。
    五、合并会计报表主要项目注释(以下金额单位若未特别注明者均为人民币元,凡未注明年初数的均为年末数)
    (一)货币资金
项       目                                                        年末数
现      金                                                   1,042,870.35
银行存款                                                   720,439,670.98
其他货币资金                                                21,863,133.29
合    计                                                   743,345,674.62
其中美元:外币金额                                           1,402,204.03
折算汇率                                                           8.2765
折合人民币                                                  11,605,341.65
港币:外币金额                                                   4,598.17
折算汇率                                                           1.0637
折合人民币                                                       4,891.07
项       目                                                        年初数
现      金                                                     846,976.14
银行存款                                                   397,885,542.67
其他货币资金                                                31,717,573.70
合    计                                                   430,450,092.51
其中美元:外币金额                                             143,166.38
折算汇率                                                           8.2765
折合人民币                                                   1,184,916.54
港币:外币金额                                                        ---
折算汇率                                                              ---
折合人民币                                                            ---
    (二)短期投资和短期投资跌价准备:
1、                                                年末数
项      目                           帐面余额                    跌价准备
股票投资                        56,296,188.76               14,862,651.00
国债投资                        51,235,650.00                1,574,400.00
其他投资                        80,000,000.00
合计                           187,531,838.76               16,437,051.00
1、                                              年初数
项      目                           帐面余额                    跌价准备
股票投资                        57,443,125.63               14,832,328.72
国债投资                        51,235,650.00                1,574,400.00
其他投资
合计                           108,678,775.63               16,406,728.72
    2、短期投资变现无重大限制。
    (三)应收票据
种      类                                                         年末数
银行承兑汇票                                                34,648,101.44
商业承兑汇票                                                16,177,229.98
合        计                                                50,825,331.42
种      类                                                         年初数
银行承兑汇票                                                88,579,889.17
商业承兑汇票                                                60,463,039.30
合        计                                               149,042,928.47
    年末已质押的应收票据:无。
    (四)应收帐款
    1、帐龄分析
                                 年      末         数
帐    龄                                      坏帐准备
                       帐面余额  占总额比例                      坏帐准备
                                              计提比例
1年以内        1,917,522,240.31      78.84%       0.5%       9,587,611.20
1-2年           213,457,280.67       8.78%        10%      21,345,728.07
2-3年            71,073,820.90       2.92%        20%      15,184,241.32
3年以上          230,124,247.42       9.46%        50%     118,017,230.34
合    计       2,432,177,589.30     100.00%                164,134,810.93
                                   年     初        数
帐    龄                                      坏帐准备
              帐面余额
                                  占总额比例                     坏帐准备
                                              计提比例
1年以内    1,599,874,773.03           75.69%      0.5%       7,999,373.87
1-2年       266,842,623.06           12.62%       10%      34,089,994.69
2-3年        66,422,560.11            3.14%       20%      14,253,989.16
3年以上      180,507,925.39            8.55%       50%      93,837,436.65
合    计   2,113,647,881.59          100.00%       ---     150,180,794.37
    2、年末应收帐款欠款金额前五名的累计总欠款金额为173,470,099.68元,占应收帐款总金额的7.13%。
    3、年末应收帐款中无持本公司5%以上(含5%)表决权股份的股东欠款。
    (五)其他应收款
    1、帐龄分析
                                     年   末   数
                                        占总额   坏帐准备
帐      龄            帐面余额                                   坏帐准备
                                          比例   计提比例
1年以内         501,055,283.91          82.86%       0.5%    2,505,276.42
1-2年           52,093,609.45           8.61%        10%    5,209,360.95
2-3年           35,927,231.67           5.94%        20%    9,518,373.74
3年以上          15,619,257.11           2.58%        50%   11,393,102.52
合    计        604,695,382.14         100.00%        ---   28,626,113.63
                                       年   初   数
                                        占总额   坏帐准备
帐      龄            帐面余额                                   坏帐准备
                                          比例   计提比例
1年以内         625,689,848.28          81.42%       0.5%    3,128,449.24
1-2年           60,680,048.83           7.90%        10%    6,068,004.88
2-3年           60,722,846.31           7.90%        20%   27,676,879.66
3年以上          21,423,374.19           2.78%        50%   17,257,576.39
合    计        768,516,117.61         100.00%        ---   54,130,910.17
    2、年末其他应收款欠款金额前五名的累计总欠款金额为150,533,366.89元,占其他应收款总金额的比例为24.89%。
    3、年末金额较大的其他应收款:
欠款人名称                                                           金额
中国华源生命产业有限公司                                    68,096,991.19
上海医药(集团)有限公司                                    54,070,000.00
香港思富有限公司                                            11,616,375.70
欠款人名称                                                     性质或内容
中国华源生命产业有限公司                                       股权转让款
上海医药(集团)有限公司                                           往来款
香港思富有限公司                                                   往来款
    4、年末其他应收款中持本公司5%以上(含5%)表决权股份的股东欠款为54,070,000.00元,详见本附注八。
    (六)预付帐款
    1、帐龄分析
                                    年   末    数
帐    龄
                      金         额                            占总额比例
1年以内              325,222,014.93                                93.92%
1-2年                20,862,033.85                                 6.02%
2-3年                   157,279.37                                 0.05%
3年以上                   50,849.80                                 0.01%
合    计             346,292,177.95                               100.00%
                                                             年   初   数
帐    龄
                      金         额                            占总额比例
1年以内              165,735,649.72                                97.97%
1-2年                 2,800,472.26                                 1.66%
2-3年                   501,751.51                                 0.30%
3年以上                  135,261.15                                 0.07%
合    计             169,173,134.64                               100.00%
帐    龄                                                   年末未收回原因
1年以内
1-2年                                                       尚未办妥结算
2-3年                                                       尚未办妥结算
3年以上                                                      尚未办妥结算
合    计
    2、年末预付帐款中无预付持本公司5%以上(含5%)表决权股份的股东单位款项。
    (七)存货及存货跌价准备
                                         年     末    数
项    目
                                   帐面余额                      跌价准备
原材料                        18,883,045.52                    535,410.69
在产品                                  ---                           ---
产成品                        17,585,081.26
库存商品                   1,257,343,666.44                 14,378,904.92
商品采购                         132,584.15
包装物                           362,998.33                    112,744.92
低值易耗品                       824,957.88
委托加工产品                     304,262.24                       9,765.3
分期收款发出商品
自制半成品                       527,303.67
合   计                    1,295,963,899.49                 15,036,825.83
                                        年       初      数
项    目
                                   帐面余额                      跌价准备
原材料                        16,195,672.74                     47,287.09
在产品                         7,875,943.54                           ---
产成品                        18,646,147.12                     19,110.19
库存商品                   1,185,385,466.33                 10,514,747.72
商品采购                                ---                           ---
包装物                         3,025,564.68                    350,232.80
低值易耗品                     2,580,304.87                     29,589.98
委托加工产品                      90,793.90                           ---
分期收款发出商品                        ---                           ---
自制半成品                       156,249.96                           ---
合   计                    1,233,956,143.14                 10,960,967.78
    年末存货按成本高于可变现净值的差额计提存货跌价准备,确定可变现净值的依据为:参照期末市场同类价。
    (八)待摊费用
类   别                                                            年初数
低值易耗品摊销                                                 120,000.00
保险费                                                         842,087.49
租赁费                                                       2,604,658.92
修理费                                                       1,989,708.45
养路费                                                          75,168.00
技术转让费                                                            ---
其   他                                                        651,018.98
合   计                                                      6,282,641.84
类   别                                                          本年增加
低值易耗品摊销                                                        ---
保险费                                                       3,202,182.03
租赁费                                                       2,679,761.54
修理费                                                       1,210,795.00
养路费                                                          24,453.00
技术转让费                                                   1,240,000.00
其   他                                                      2,901,793.39
合   计                                                     11,258,984.96
类   别                                                          本年摊销
低值易耗品摊销                                                        ---
保险费                                                       3,478,388.10
租赁费                                                       1,841,944.80
修理费                                                       1,128,022.83
养路费                                                          42,942.90
技术转让费                                                     103,333.33
其   他                                                        737,624.39
合   计                                                      7,332,256.35
类   别                                                            年末数
低值易耗品摊销                                                 120,000.00
保险费                                                         565,881.42
租赁费                                                       3,442,475.66
修理费                                                       2,072,480.62
养路费                                                          56,678.10
技术转让费                                                   1,136,666.67
其   他                                                      2,815,187.98
合   计                                                     10,209,370.45
    (九)一年内到期的长期债权投资:
年    末     数                                           年    初     数
---                                                                   ---
    (十)长期投资:
项        目                                     年    末    数
                                 帐面余额                        减值准备
长期股权投资               489,807,906.89                      137,087.25
长期债权投资                          ---                             ---
小计                       489,807,906.89                      137,087.25
项        目                                      年    初     数
                                 帐面余额                        减值准备
长期股权投资               455,267,789.36                    7,297,817.94
长期债权投资                       990.00                             ---
小计                       455,268,779.36                    7,297,817.94
    1、长期股权投资:
    (1)股票投资:
                                                                 股票数量
被投资公司名称               股份类别
                                                                   (股)
ST中科                         法人股                              25,200
百联股份                       法人股                              33,324
长江股份                       法人股                             112,590
小计
                         占被投资公司
被投资公司名称                                               初始投资成本
                         注册资本比例
ST中科                            <1%                           99,300.00
百联股份                          <1%                           65,450.00
长江股份                          <1%                          158,749.00
小计                                                           323,499.00
被投资公司名称                                   年末帐面余额年初帐面余额
ST中科                      99,300.00                           99,300.00
百联股份                    65,450.00                           65,450.00
长江股份                   158,749.00                          158,749.00
小计                       323,499.00                          323,499.00
    (2)其他股权投资:
    A、成本法核算的股权投资:
被投资单位名称                                                 投资起止期
上海市长宁区医药有限公司                                        1996-2016
交通银行                                                           无期限
上海药房股份有限公司                                            1997-2017
上海新时代药业股份有限公司                                      2000-2019
上海申银万国证券股份有限公司                                       无期限
长江经济联合发展股份有限公司                                       无期限
上海申威医药有限公司                                            1999-2007
上海医药血液技术产业发展有限公司                                2001-2036
上海云湖医药药材股份有限公司                                       无期限
上海雷允上北区药业有限公司                                         无期限
上海鲲鹏投资发展有限公司                                           无期限
上海复旦张江生物医药股份有限公司                                1999-2023
上海英达莱置业有限公司                                          1989-2009
上海医药绿色联盟大药房连锁有限公司                              2004-5-1-
宁波药材股份有限公司                                               无年限
宁波申甬医药物流有限公司                                             10年
深圳中联广深医药股份有限公司                                       无期限
上海华氏北部大药房有限公司                                         无期限
南通华氏佳源医药有限公司                                             30年
合计
                                                             占被投资单位
被投资单位名称
                                                             注册资本比例
上海市长宁区医药有限公司                                           15.30%
交通银行                                                              <1%
上海药房股份有限公司                                                8.00%
上海新时代药业股份有限公司                                         20.00%
上海申银万国证券股份有限公司                                          <1%
长江经济联合发展股份有限公司                                          <1%
上海申威医药有限公司                                               30.00%
上海医药血液技术产业发展有限公司                                   10.00%
上海云湖医药药材股份有限公司                                        4.54%
上海雷允上北区药业有限公司                                          5.00%
上海鲲鹏投资发展有限公司                                           10.00%
上海复旦张江生物医药股份有限公司                                   19.66%
上海英达莱置业有限公司                                             14.75%
上海医药绿色联盟大药房连锁有限公司                                    23%
宁波药材股份有限公司                                                 <1%
宁波申甬医药物流有限公司                                              10%
深圳中联广深医药股份有限公司                                        3.16%
上海华氏北部大药房有限公司                                         10.00%
南通华氏佳源医药有限公司                                            8.00%
合计
被投资单位名称                                                   期初余额
上海市长宁区医药有限公司                                       500,000.00
交通银行                                                       884,503.40
上海药房股份有限公司                                         2,920,000.00
上海新时代药业股份有限公司                                   3,000,000.00
上海申银万国证券股份有限公司                                20,000,000.00
长江经济联合发展股份有限公司                                   280,000.00
上海申威医药有限公司                                         1,200,000.00
上海医药血液技术产业发展有限公司                               600,000.00
上海云湖医药药材股份有限公司                                   632,978.00
上海雷允上北区药业有限公司                                   3,002,360.00
上海鲲鹏投资发展有限公司                                     8,263,436.00
上海复旦张江生物医药股份有限公司                            19,147,723.08
上海英达莱置业有限公司                                      29,500,000.00
上海医药绿色联盟大药房连锁有限公司                             600,000.00
宁波药材股份有限公司                                            32,568.00
宁波申甬医药物流有限公司                                        50,000.00
深圳中联广深医药股份有限公司                                 3,283,773.00
上海华氏北部大药房有限公司                                      50,000.00
南通华氏佳源医药有限公司                                       400,000.00
合计                                                        94,347,341.48
被投资单位名称                                             本期投资增减额
上海市长宁区医药有限公司                                       811,968.20
交通银行                                                              ---
上海药房股份有限公司                                                  ---
上海新时代药业股份有限公司                                            ---
上海申银万国证券股份有限公司                                          ---
长江经济联合发展股份有限公司                                          ---
上海申威医药有限公司                                                  ---
上海医药血液技术产业发展有限公司                                      ---
上海云湖医药药材股份有限公司                                          ---
上海雷允上北区药业有限公司                                            ---
上海鲲鹏投资发展有限公司                                              ---
上海复旦张江生物医药股份有限公司                                      ---
上海英达莱置业有限公司                                                ---
上海医药绿色联盟大药房连锁有限公司                                    ---
宁波药材股份有限公司                                                  ---
宁波申甬医药物流有限公司                                              ---
深圳中联广深医药股份有限公司                                          ---
上海华氏北部大药房有限公司                                     -50,000.00
南通华氏佳源医药有限公司                                              ---
合计                                                           761,968.20
被投资单位名称                                               期末帐面余额
上海市长宁区医药有限公司                                     1,311,968.20
交通银行                                                       884,503.40
上海药房股份有限公司                                         2,920,000.00
上海新时代药业股份有限公司                                   3,000,000.00
上海申银万国证券股份有限公司                                20,000,000.00
长江经济联合发展股份有限公司                                   280,000.00
上海申威医药有限公司                                         1,200,000.00
上海医药血液技术产业发展有限公司                               600,000.00
上海云湖医药药材股份有限公司                                   632,978.00
上海雷允上北区药业有限公司                                   3,002,360.00
上海鲲鹏投资发展有限公司                                     8,263,436.00
上海复旦张江生物医药股份有限公司                            19,147,723.08
上海英达莱置业有限公司                                      29,500,000.00
上海医药绿色联盟大药房连锁有限公司                             600,000.00
宁波药材股份有限公司                                            32,568.00
宁波申甬医药物流有限公司                                        50,000.00
深圳中联广深医药股份有限公司                                          ---
上海华氏北部大药房有限公司                                            ---
南通华氏佳源医药有限公司                                       400,000.00
合计                                                        91,825,536.68
    B、权益法核算的对子公司股权投资:
                                   投资                      占被投资单位
被投资单位名称
                                 起止期                      注册资本比例
上海华氏医药储
运有限公司                  1994-无期限                           100.00%
香港思富有限公
司                            1996-2011                            99.98%
上海市医药股份
有限公司池州华
氏公司                        1998-2028                            55.00%
上海金山医药药
材有限公司                    1997-2017                            51.00%
安徽华氏医药有
限公司                        2000-2019                            67.00%
上海华氏经济发
展有限公司                    2001-2017                           100.00%
上海制药(苏丹)
有限公司                      1998-2027                            55.00%
上海市一大药房
有限公司                    2002-无期限                            60.00%
上海健尔药房有
限公司                        2002-2007                            50.00%
上海华天广告有
限公司                        1990-2010                           100.00%
上海华氏国贸医
药有限公司                    2003-2023                            90.00%
太湖华氏医药有
限公司                      2003-无期限                            54.25%
江西华康药业有
限公司                           无期限                            64.25%
通用三公司                       无期限                            60.00%
江西南华医药有
限公司                            2001-                            50.00%
上海华嘉有限公
司                            2001-2021                            46.00%
上海罗达医药有
限公司                          2003.11                            20.00%
上海天平实业有
限公司                      1985-无期限                           100.00%
上海天平制药厂
保健食品分厂                  2000-2014                            60.00%
上海天平胃舒平
制药厂                                                             39.00%
合计                                                                0.00%
被投资单位名称                          期初余额
                                                                 本期合计
上海华氏医药储
运有限公司                          5,075,335.71                16,325.71
香港思富有限公
司                                  8,901,801.67               525,766.28
上海市医药股份
有限公司池州华
氏公司                              1,322,281.54                25,257.78
上海金山医药药
材有限公司                          5,510,392.44                14,683.99
安徽华氏医药有
限公司                              2,310,879.08                18,536.41
上海华氏经济发
展有限公司                          3,089,942.14              -610,867.45
上海制药(苏丹)
有限公司                           16,322,461.11              -117,394.36
上海市一大药房
有限公司                            1,253,546.37                49,422.03
上海健尔药房有
限公司                              1,005,079.46               270,938.91
上海华天广告有
限公司                              2,184,418.25               -62,807.42
上海华氏国贸医
药有限公司                          7,312,456.51            -1,937,099.26
太湖华氏医药有
限公司                                300,000.00                      ---
江西华康药业有
限公司                                323,499.00              -323,499.00
通用三公司                          2,800,000.00            -2,800,000.00
江西南华医药有
限公司                             93,016,061.78               751,423.73
上海华嘉有限公
司                                    937,889.18              -937,889.18
上海罗达医药有
限公司                              1,294,897.77               107,542.07
上海天平实业有
限公司                                385,511.07                  -191.19
上海天平制药厂
保健食品分厂                          653,889.93                 4,152.09
上海天平胃舒平
制药厂                              3,587,672.02               532,670.72
合计                              157,588,015.03            -4,473,028.16
                                  本期权益增减额
被投资单位名称
                                  其中:投资成本                 确认收益
上海华氏医药储
运有限公司                                   ---                16,325.71
香港思富有限公
司                                           ---               525,766.28
上海市医药股份
有限公司池州华
氏公司                                       ---                25,257.78
上海金山医药药
材有限公司                                   ---               175,391.83
安徽华氏医药有
限公司                                       ---                18,536.41
上海华氏经济发
展有限公司                                   ---              -610,867.45
上海制药(苏丹)
有限公司                                     ---              -117,394.36
上海市一大药房
有限公司                                     ---               195,022.03
上海健尔药房有
限公司                                       ---               270,938.91
上海华天广告有                        -67,000.00
限公司                                                           4,192.58
上海华氏国贸医
药有限公司                                   ---            -1,937,099.26
太湖华氏医药有
限公司                                       ---                      ---
江西华康药业有
限公司                               -323,499.00                      ---
通用三公司                         -2,800,000.00                      ---
江西南华医药有
限公司                                       ---               751,423.73
上海华嘉有限公
司                                           ---              -937,889.18
上海罗达医药有
限公司                                       ---               107,542.07
上海天平实业有
限公司                                116,721.31              -116,912.50
上海天平制药厂
保健食品分厂                          -72,392.23                76,544.32
上海天平胃舒平
制药厂                                       ---               532,670.72
合计                               -3,146,169.92            -1,020,550.40
被投资单位名称                          差额摊销
                                                                 分得利润
上海华氏医药储
运有限公司                                   ---                      ---
香港思富有限公
司                                           ---                      ---
上海市医药股份
有限公司池州华
氏公司                                       ---                      ---
上海金山医药药
材有限公司                                   ---               160,707.84
安徽华氏医药有
限公司                                       ---                      ---
上海华氏经济发
展有限公司                                   ---                      ---
上海制药(苏丹)
有限公司                                     ---                      ---
上海市一大药房
有限公司                                     ---               145,600.00
上海健尔药房有
限公司                                       ---                      ---
上海华天广告有
限公司                                       ---                      ---
上海华氏国贸医
药有限公司                                   ---                      ---
太湖华氏医药有
限公司                                       ---                      ---
江西华康药业有
限公司                                       ---                      ---
通用三公司                                   ---                      ---
江西南华医药有
限公司                                       ---                      ---
上海华嘉有限公
司                                           ---                      ---
上海罗达医药有
限公司                                       ---                      ---
上海天平实业有
限公司                                       ---                      ---
上海天平制药厂
保健食品分厂                                 ---                      ---
上海天平胃舒平
制药厂                                       ---                      ---
合计                                         ---               306,307.84
                                                                 期末余额
被投资单位名称
                                        初始投资                 累计增减
上海华氏医药储
运有限公司                          5,511,409.00              -419,747.58
香港思富有限公
司                                  6,000,000.00             3,427,567.95
上海市医药股份
有限公司池州华
氏公司                                467,500.00               880,039.32
上海金山医药药
材有限公司                          5,100,000.00               425,076.43
安徽华氏医药有
限公司                              2,150,000.00               179,415.49
上海华氏经济发
展有限公司                          4,953,562.00            -2,474,487.31
上海制药(苏丹)
有限公司                            9,043,016.00             7,162,050.75
上海市一大药房
有限公司                              660,000.00               642,968.40
上海健尔药房有
限公司                                500,000.00               776,018.37
上海华天广告有
限公司                              1,512,000.00               609,610.83
上海华氏国贸医
药有限公司                          8,300,000.00            -2,924,642.75
太湖华氏医药有
限公司                                300,000.00                      ---
江西华康药业有
限公司                              1,510,000.00            -1,510,000.00
通用三公司                                   ---                      ---
江西南华医药有
限公司                             90,000,000.00             3,767,485.51
上海华嘉有限公
司                                  2,000,000.00            -2,000,000.00
上海罗达医药有
限公司                              1,000,000.00               402,439.84
上海天平实业有
限公司                                383,278.69                 2,041.19
上海天平制药厂
保健食品分厂                          282,392.23               375,649.79
上海天平胃舒平
制药厂                              2,340,000.00             1,780,342.74
合计                              142,013,157.92            11,101,828.95
被投资单位名称
                                                                     合计
上海华氏医药储
运有限公司                                                   5,091,661.42
香港思富有限公
司                                                           9,427,567.95
上海市医药股份
有限公司池州华
氏公司                                                       1,347,539.32
上海金山医药药
材有限公司                                                   5,525,076.43
安徽华氏医药有
限公司                                                       2,329,415.49
上海华氏经济发
展有限公司                                                   2,479,074.69
上海制药(苏丹)
有限公司                                                    16,205,066.75
上海市一大药房
有限公司                                                     1,302,968.40
上海健尔药房有
限公司                                                       1,276,018.37
上海华天广告有
限公司                                                       2,121,610.83
上海华氏国贸医
药有限公司                                                   5,375,357.25
太湖华氏医药有
限公司                                                         300,000.00
江西华康药业有
限公司                                                                ---
通用三公司                                                            ---
江西南华医药有
限公司                                                      93,767,485.51
上海华嘉有限公
司                                                                  -0.00
上海罗达医药有
限公司                                                       1,402,439.84
上海天平实业有
限公司                                                         385,319.88
上海天平制药厂
保健食品分厂                                                   658,042.02
上海天平胃舒平
制药厂                                                       4,120,342.74
合计                                                       153,114,986.87
    C、对合营企业股权投资:
被投资单位名称                          投资                 占被投资单位
                                      起止期                 注册资本比例
重庆医药上海药品
销售有限公司                       1996-2006                       49.00%
上海市闸北区医药
有限公司                           1997-2017                          ---
上海医药商务网络
有限公司                           1999-2019                       38.75%
吉林亚泰华氏医药
有限公司                           2001-2020                       48.00%
上海华源长富药业
(集团)有限公司                     1999-2029                       24.13%
上海先导药业有限
公司                                  无期限                       24.00%
江西省医药管理局
庐山培训基地                          无期限                       48.39%
宁海县四明大药房
有限公司                              无期限                       29.00%
上海大明置业有限
公司                          1995.5-无期限                       25.00%
宁波联合医疗器械
化试玻仪有限公司                1994-无期限                       25.00%
上海绿苑药房有限
公司                               2000-2010                       30.00%
上海华翔药业有限
公司                               2003-2023                       27.00%
上海医药物流中心
有限公司                                                           38.57%
合计
被投资单位名称                            期初余额
                                                                 本期合计
重庆医药上海药品
销售有限公司                          1,772,928.31             139,983.05
上海市闸北区医药
有限公司                                       ---                    ---
上海医药商务网络
有限公司                              3,607,247.64             -76,405.08
吉林亚泰华氏医药
有限公司                              5,400,661.07             -10,986.48
上海华源长富药业
(集团)有限公司                      128,256,835.00           2,079,163.22
上海先导药业有限
公司                                  2,647,672.46                    ---
江西省医药管理局
庐山培训基地                          1,144,309.63          -1,144,309.63
宁海县四明大药房
有限公司                                248,466.34                    ---
上海大明置业有限
公司                                    137,087.25                    ---
宁波联合医疗器械
化试玻仪有限公司                        787,315.05            -150,000.00
上海绿苑药房有限
公司                                    876,802.62             215,494.22
上海华翔药业有限
公司                                  1,375,282.61                    ---
上海医药物流中心
有限公司                                       ---           3,000,000.00
合计                                146,254,607.98           4,052,939.30
被投资单位名称                                   本期权益增减额
                                         其中:投资成本          确认收益
重庆医药上海药品
销售有限公司                                        ---        139,983.05
上海市闸北区医药
有限公司                                            ---
上海医药商务网络
有限公司                                            ---        -76,405.08
吉林亚泰华氏医药
有限公司                                            ---        211,661.28
上海华源长富药业
(集团)有限公司                                      ---      2,079,163.22
上海先导药业有限
公司                                                ---               ---
江西省医药管理局
庐山培训基地                              -1,144,309.63               ---
宁海县四明大药房
有限公司                                            ---               ---
上海大明置业有限
公司                                                ---               ---
宁波联合医疗器械                                              -150,000.00
化试玻仪有限公司                                    ---
上海绿苑药房有限
公司                                                ---        275,494.22
上海华翔药业有限
公司                                                ---               ---
上海医药物流中心
有限公司                                   3,000,000.00               ---
合计                                       1,855,690.37      2,479,896.69
被投资单位名称
                                               差额摊销          分得利润
重庆医药上海药品
销售有限公司                                        ---               ---
上海市闸北区医药
有限公司                                            ---               ---
上海医药商务网络
有限公司                                            ---               ---
吉林亚泰华氏医药
有限公司                                            ---               ---
上海华源长富药业
(集团)有限公司                                      ---               ---
上海先导药业有限
公司                                                ---               ---
江西省医药管理局
庐山培训基地                                        ---               ---
宁海县四明大药房
有限公司                                            ---               ---
上海大明置业有限
公司                                                ---               ---
宁波联合医疗器械
化试玻仪有限公司                                    ---               ---
上海绿苑药房有限
公司                                                ---               ---
上海华翔药业有限
公司                                                ---               ---
上海医药物流中心
有限公司                                            ---               ---
合计                                                ---               ---
被投资单位名称                                                   期末余额
                                               初始投资          累计增减
重庆医药上海药品
销售有限公司                                 980,000.00        932,911.36
上海市闸北区医药
有限公司                                   2,100,000.00     -2,100,000.00
上海医药商务网络
有限公司                                   8,125,000.00     -4,594,157.44
吉林亚泰华氏医药
有限公司                                   4,800,000.00        589,674.59
上海华源长富药业
(集团)有限公司                            77,616,942.78     52,719,055.44
上海先导药业有限
公司                                       3,600,000.00       -952,327.54
江西省医药管理局
庐山培训基地                               1,200,000.00     -1,200,000.00
宁海县四明大药房
有限公司                                     435,000.00       -186,533.66
上海大明置业有限
公司                                       2,500,000.00     -2,362,912.75
宁波联合医疗器械
化试玻仪有限公司                             300,000.00        337,315.05
上海绿苑药房有限
公司                                         150,000.00        942,296.84
上海华翔药业有限
公司                                       1,350,000.00         25,282.61
上海医药物流中心
有限公司                                   3,000,000.00               ---
合计                                     106,156,942.78     44,150,604.50
被投资单位名称
                                                                     合计
重庆医药上海药品
销售有限公司                                                 1,912,911.36
上海市闸北区医药
有限公司                                                              ---
上海医药商务网络
有限公司                                                     3,530,842.56
吉林亚泰华氏医药
有限公司                                                     5,389,674.59
上海华源长富药业
(集团)有限公司                                             130,335,998.22
上海先导药业有限
公司                                                         2,647,672.46
江西省医药管理局
庐山培训基地                                                          ---
宁海县四明大药房
有限公司                                                       248,466.34
上海大明置业有限
公司                                                           137,087.25
宁波联合医疗器械
化试玻仪有限公司                                               637,315.05
上海绿苑药房有限
公司                                                         1,092,296.84
上海华翔药业有限
公司                                                         1,375,282.61
上海医药物流中心
有限公司                                                     3,000,000.00
合计                                                       150,307,547.28
    2、长期债权投资:
    债券投资:
债券种类           面值       年利率        初始投资成本           到期日
---                 ---          ---                 ---              ---
                                         累计应收
债券种类          年初余额   本年利息                 年末余额   减值准备
                                        (已收)利息
---                   ---       ---          ---          ---       ---
    3、长期投资减值准备
    长期股权投资减值准备:
被投资单位名称                                                     年初数
上海大明置业有限公司                                                  ---
被投资单位名称                                                   本年增加
上海大明置业有限公司                                           137,087.25
被投资单位名称                                                   本年转出
上海大明置业有限公司                                                  ---
被投资单位名称                                                     年末数
上海大明置业有限公司                                           137,087.25
    4、构成合并价差的股权投资差额:
被投资单位名称                                                   初始金额
上海华氏大药房有限公司                                         166,118.93
上海福达制药有限公司                                         1,022,209.82
上海思富医药有限公司                                          -679,687.30
上海华仁医药有限公司                                        -1,523,464.21
上海华氏医药西部大药房有限公司                                -288,756.90
上海闵行区药材医药有限公司                                   3,000,000.00
青岛华氏国风医药有限公司                                     9,059,689.03
杭州华氏医药有限公司                                         3,834,058.75
福建康源医药有限公司                                        10,933,996.88
嘉兴华氏大药房兰台零售连锁有限公司                           4,500,000.00
宁波医药股份有限公司                                        46,350,025.99
宁波四明大药房有限公司                                       7,023,580.37
宁波亚太生物科技有限公司                                    13,396,461.66
象山医药药材有限公司                                         1,030,573.36
宁海医药药材有限责任公司                                        27,992.75
小计                                                        97,852,799.13
被投资单位名称                                                   形成原因
上海华氏大药房有限公司                                           溢价投入
上海福达制药有限公司                                                  ---
上海思富医药有限公司                                                  ---
上海华仁医药有限公司                                                  ---
上海华氏医药西部大药房有限公司                                        ---
上海闵行区药材医药有限公司                                       溢价收购
青岛华氏国风医药有限公司                                         溢价收购
杭州华氏医药有限公司                                             溢价收购
福建康源医药有限公司                                             溢价收购
嘉兴华氏大药房兰台零售连锁有限公司                               溢价投入
宁波医药股份有限公司                                             溢价收购
宁波四明大药房有限公司                                           溢价收购
宁波亚太生物科技有限公司                                         溢价收购
象山医药药材有限公司                                             溢价收购
宁海医药药材有限责任公司                                         溢价收购
小计
被投资单位名称                                                   摊销期限
上海华氏大药房有限公司                                               10年
上海福达制药有限公司                                                  8年
上海思富医药有限公司                                                 15年
上海华仁医药有限公司                                                 15年
上海华氏医药西部大药房有限公司                                       10年
上海闵行区药材医药有限公司                                           20年
青岛华氏国风医药有限公司                                             20年
杭州华氏医药有限公司                                                 15年
福建康源医药有限公司                                                 20年
嘉兴华氏大药房兰台零售连锁有限公司                                   10年
宁波医药股份有限公司                                                 50年
宁波四明大药房有限公司                                               50年
宁波亚太生物科技有限公司                                             50年
象山医药药材有限公司                                                 10年
宁海医药药材有限责任公司                                             10年
小计
被投资单位名称                                                 本年摊销额
上海华氏大药房有限公司                                           8,305.95
上海福达制药有限公司                                            63,888.12
上海思富医药有限公司                                           -22,656.25
上海华仁医药有限公司                                           -50,782.14
上海华氏医药西部大药房有限公司
上海闵行区药材医药有限公司                                      75,000.00
青岛华氏国风医药有限公司                                       226,492.23
杭州华氏医药有限公司                                           127,801.96
福建康源医药有限公司                                           273,349.92
嘉兴华氏大药房兰台零售连锁有限公司                             225,000.00
宁波医药股份有限公司                                           463,500.26
宁波四明大药房有限公司                                          70,235.80
宁波亚太生物科技有限公司                                       133,964.64
象山医药药材有限公司                                            51,528.66
宁海医药药材有限责任公司                                         1,399.64
小计                                                         1,647,028.78
被投资单位名称                                                   摊余金额
上海华氏大药房有限公司                                         141,201.10
上海福达制药有限公司                                           447,216.79
上海思富医药有限公司                                          -362,499.88
上海华仁医药有限公司                                          -812,514.24
上海华氏医药西部大药房有限公司                                -202,129.84
上海闵行区药材医药有限公司                                   2,625,000.00
青岛华氏国风医药有限公司                                     8,380,212.36
杭州华氏医药有限公司                                         3,450,652.87
福建康源医药有限公司                                        10,113,947.12
嘉兴华氏大药房兰台零售连锁有限公司                           3,825,000.00
宁波医药股份有限公司                                        45,886,525.73
宁波四明大药房有限公司                                       6,953,344.57
宁波亚太生物科技有限公司                                    13,262,497.02
象山医药药材有限公司                                           515,286.76
宁海医药药材有限责任公司                                        12,596.71
小计                                                        94,236,337.06
    (十二)固定资产原价及累计折旧
    1、固定资产原价
类     别                        年初原价                        本年增加
房屋及建筑物               797,484,488.10                  102,814,358.44
通用设备                   248,329,356.88                   34,041,615.14
专用设备                    74,641,118.21                    4,046,170.92
运输工具                    57,048,133.06                   15,994,560.00
固定资产装修                   480,440.00
合      计               1,177,983,536.25                  156,896,705.50
类     别                        本年减少                        年末原价
房屋及建筑物               106,562,866.71                  793,735,979.83
通用设备                    20,602,586.04                  261,768,385.98
专用设备                    11,618,652.32                   67,068,636.81
运输工具                    13,278,747.60                   59,763,946.46
固定资产装修                                                   480,440.00
合      计                 152,062,852.67                1,182,817,389.08
    其中:本年由在建工程转入固定资产原价为10,757,004.19元。年末已抵押的固定资产原价为65,703,002.32元。详见附注十(二)。
    2、累计折旧
类         别                                                      年初数
房屋及建筑物                                               143,243,386.88
通用设备                                                    86,975,037.41
专用设备                                                    37,439,486.41
运输工具                                                    32,029,054.42
固定资产装修                                                    66,697.93
合            计                                           299,753,663.05
类         别                                                    本年增加
房屋及建筑物                                                16,684,268.53
通用设备                                                     8,330,126.72
专用设备                                                       885,727.63
运输工具                                                     7,183,475.15
固定资产装修
合            计                                            33,083,598.03
类         别                                                    本年提取
房屋及建筑物                                                13,157,409.11
通用设备                                                    13,930,921.24
专用设备                                                     2,338,955.53
运输工具                                                     2,632,915.97
固定资产装修                                                    30,943.08
合            计                                            32,091,144.93
类         别                                                    本年减少
房屋及建筑物                                                26,861,414.38
通用设备                                                    10,569,540.19
专用设备                                                     5,399,985.24
运输工具                                                     8,000,022.86
固定资产装修
合            计                                            50,830,962.67
类         别                                                      年末数
房屋及建筑物                                               146,223,650.14
通用设备                                                    98,666,545.19
专用设备                                                    35,264,184.33
运输工具                                                    33,845,422.68
固定资产装修                                                    97,641.01
合            计                                           314,097,443.35
    3、固定资产减值准备
类别                                 年 初 数                    本年增加
房屋及建筑物                        1,897,461.13                16,381.61
通用设备                            1,523,809.48             2,246,933.54
专用设备                              165,271.41
运输工具                               24,016.98                63,909.75
合            计                    3,610,559.00             2,327,224.90
类别                                    本年减少     年       末       数
房屋及建筑物                                                 1,913,842.74
通用设备                              476,902.63             3,293,840.39
专用设备                                                       165,271.41
运输工具                                                        87,926.73
合            计                      476,902.63             5,460,881.27
    注:固定资产减值准备本年减少系出售或报废固定资产相应转销数。
    4、已提足折旧仍继续使用的固定资产
类            别                                                 帐面原值
房屋及建筑物                                                    64,630.00
通用设备                                                     1,320,346.76
专用设备                                                       503,512.00
运输工具                                                     1,029,766.90
合计                                                         2,918,255.66
类            别                                                 累计折旧
房屋及建筑物                                                    61,542.26
通用设备                                                     1,077,708.42
专用设备                                                       406,556.86
运输工具                                                       994,305.26
合计                                                         2,540,112.80
类            别                                                 帐面净值
房屋及建筑物                                                     3,087.74
通用设备                                                       242,638.34
专用设备                                                        96,955.14
运输工具                                                        35,461.64
合计                                                           378,142.86
    (十三)在建工程
工程项目名称                                                       年初数
新开零售门店                                                 1,921,674.41
天平迁址项目                                                 7,059,135.77
GMP改造项目                                                  1,610,500.00
长乐厂GMP改造项目                                            5,259,176.00
未来岛投资置业                                              44,820,000.00
江杨库屋面改造工程                                             250,000.00
医药连锁和现代物流                                          85,631,105.98
禾丰新建成品仓库                                                 598,8740
禾丰针剂车间GMP改造                                          1,192,000.00
安庆开发区中药饮片厂工
程                                                                    ---
通用制药厂向化铝管工程                                       1,412,320.56
外高桥仓库改造二、三期
工程                                                              701,226
ERP系统整合升级                                                   620,100
固定资产购置                                                      734,800
零星工程等                                                   3,282,596.04
药品生产线                                                     616,998.54
合          计                                             155,710,559.30
工程项目名称                                                     本年增加
新开零售门店                                                          ---
天平迁址项目                                                 5,368,636.20
GMP改造项目                                                           ---
长乐厂GMP改造项目                                              943,708.00
未来岛投资置业                                              11,000,000.00
江杨库屋面改造工程                                                    ---
医药连锁和现代物流                                          41,462,865.58
禾丰新建成品仓库                                             2,138,166.22
禾丰针剂车间GMP改造                                          4,705,261.34
安庆开发区中药饮片厂工
程                                                             334,462.92
通用制药厂向化铝管工程                                                ---
外高桥仓库改造二、三期
工程                                                           298,000.00
ERP系统整合升级                                                   200,000
固定资产购置                                                      381,900
零星工程等                                                   2,646,205.93
药品生产线                                                            ---
合          计                                              69,479,206.19
                                                                 本年减少
工程项目名称                                                 转入固定资产
新开零售门店                                                   499,739.21
天平迁址项目                                                 3,647,001.35
GMP改造项目                                                           ---
长乐厂GMP改造项目                                                     ---
未来岛投资置业                                                        ---
江杨库屋面改造工程                                                    ---
医药连锁和现代物流                                                    ---
禾丰新建成品仓库                                             1,256,424.22
禾丰针剂车间GMP改造                                          4,565,546.14
安庆开发区中药饮片厂工
程                                                                    ---
通用制药厂向化铝管工程                                                ---
外高桥仓库改造二、三期
工程                                                                  ---
ERP系统整合升级                                                       ---
固定资产购置                                                          ---
零星工程等                                                     377,164.71
药品生产线                                                            ---
合          计                                              10,345,875.63
                                                                 本年减少
工程项目名称                                                     其他减少
新开零售门店                                                        5,222
天平迁址项目                                                        1,998
GMP改造项目                                                           ---
长乐厂GMP改造项目                                               10,000.00
未来岛投资置业                                                        ---
江杨库屋面改造工程                                                    ---
医药连锁和现代物流                                                    ---
禾丰新建成品仓库                                                      ---
禾丰针剂车间GMP改造                                                   ---
安庆开发区中药饮片厂工
程                                                                    ---
通用制药厂向化铝管工程                                         489,402.44
外高桥仓库改造二、三期
工程                                                                  ---
ERP系统整合升级                                                       ---
固定资产购置                                                          ---
零星工程等                                                       60,335.5
药品生产线                                                            ---
合          计                                                 566,957.94
工程项目名称                                                       年末数
新开零售门店                                                  1,416,713.2
天平迁址项目                                                 8,778,772.62
GMP改造项目                                                  1,610,500.00
长乐厂GMP改造项目                                            6,192,884.00
未来岛投资置业                                              55,820,000.00
江杨库屋面改造工程                                             250,000.00
医药连锁和现代物流                                         127,093,971.56
禾丰新建成品仓库                                             1,480,616.00
禾丰针剂车间GMP改造                                          1,331,715.20
安庆开发区中药饮片厂工
程                                                             334,462.92
通用制药厂向化铝管工程                                         922,918.12
外高桥仓库改造二、三期
工程                                                           999,226.00
ERP系统整合升级                                                   820,100
固定资产购置                                                    1,116,700
零星工程等                                                   5,491,301.76
药品生产线                                                     616,998.54
合          计                                             214,276,879.92
工程项目名称                                                     资金来源
新开零售门店                                                         自筹
天平迁址项目                                                         自筹
GMP改造项目                                                          自筹
长乐厂GMP改造项目                                                    自筹
未来岛投资置业                                                 自筹、贷款
江杨库屋面改造工程                                                   自筹
医药连锁和现代物流                                             自筹、贷款
禾丰新建成品仓库                                                     自筹
禾丰针剂车间GMP改造                                                  自筹
安庆开发区中药饮片厂工                                               自筹

通用制药厂向化铝管工程                                               自筹
外高桥仓库改造二、三期                                               自筹
工程
ERP系统整合升级                                                      自筹
固定资产购置                                                         自筹
零星工程等                                                           贷款
药品生产线                                                           自筹
合          计
工程项目名称                                                     项目进度
新开零售门店                                                          80%
天平迁址项目                                                          85%
GMP改造项目                                                           90%
长乐厂GMP改造项目                                                     95%
未来岛投资置业                                                        70%
江杨库屋面改造工程                                                    20%
医药连锁和现代物流                                                    85%
禾丰新建成品仓库                                                     90%
禾丰针剂车间GMP改造                                                  90%
安庆开发区中药饮片厂工                                                10%

通用制药厂向化铝管工程                                              100%
外高桥仓库改造二、三期                                              100%
工程
ERP系统整合升级                                                       20%
固定资产购置                                                          90%
零星工程等                                                            96%
药品生产线                                                            90%
合          计
    1、其中借款费用资本化金额
工程项目名称      年初数  本年增加  本年转入固定资产额  其他减少   年末数
    2、在建工程减值准备
项目名称                              年初数                     本年增加
GMP改造项目                     1,610,500.00
药品生产线                        616,998.54
合计                            2,227,498.54
项目名称                            本年减少                       年末数
GMP改造项目                                                  1,610,500.00
药品生产线                                                     616,998.54
合计                                                         2,227,498.54
项目名称                                                         计提原因
GMP改造项目                                      长期停工预计不会重新开工
药品生产线                                             长期呆滞工程已报废
合计
    (十四)无形资产
1、类            别                         取得方式             原始金额
土地使用权                            股东投入、购入       140,142,148.10
房屋使用权                                      购入                  ---
技术转让费                                  股东投入         1,984,800.00
计算机软件                                      购入        10,132,165.29
许可证照                              股东投入、购入        17,332,400.00
电话号码                                        购入           320,497.25
其他                                            购入         3,000,000.00
合计                                                       172,912,010.64
1、类            别                         年初数               本年增加
土地使用权                          132,650,142.93          10,641,455.02
房屋使用权                                     ---                    ---
技术转让费                            1,190,880.00             132,500.00
计算机软件                           10,296,571.53           1,727,237.78
许可证照                              1,199,976.00                    ---
电话号码                                288,447.53
其他                                  1,533,333.06
合计                                147,159,351.05          12,501,192.80
1、类            别                         本年转出             本年摊销
土地使用权                             35,697,506.71        1,628,702.46-
房屋使用权                                       ---                  ---
技术转让费                                       ---                  ---
计算机软件                              3,777,911.13           853,005.03
许可证照                                  500,000.00            50,113.00
电话号码
其他                                                             31246.74
合计                                   39,975,417.84         2,681,057.23
1、类            别                           年末数         剩余摊销期限
土地使用权                           105,965,388.78           66-758 个月
房屋使用权                                       ---                  ---
技术转让费                              1,205,390.00               66个月
计算机软件                              7,392,893.15            71-94个月
许可证照                                 649,863.00-            14-78个月
电话号码                                  288,447.53                  ---
其他                                    1,502,086.32               86个月
合计                                  117,004,068.78
    注:本期增加及转出系因为合并单位发生增减所致。
    2、计提减值准备
类别                                                               年末数
电话号码                                                       288,447.53
类别                                                               年初数
电话号码                                                       288,447.53
类别                                                             计提原因
电话号码                                                       无变现价值
    (十五)长期待摊费用
项    目                                     原始金额              年初数
装修费                                            ---       21,174,660.96
租入固定资产改良支出                     3,218,929.03        2,634,053.12
技术受让费                              12,300,000.00       17,863,250.87
公用设施增容费                           4,112,930.52        1,850,846.52
电子交易网                               2,215,144.87          657,998.07
其他递延支出                                      ---        3,659,842.12
合计                                                        47,840,651.66
项    目                                     本年增加            本年减少
装修费                                   3,470,621.16         6,531,18.70
租入固定资产改良支出
技术受让费                                 700,000.00
公用设施增容费
电子交易网
其他递延支出                                24,498.40          464,103.17
合计                                     4,195,119.56        1,117,221.87
项    目                                     本年摊销              年末数
装修费                                   3,688,849.20       20,303,314.22
租入固定资产改良支出                                         2,634,053.12
技术受让费                               1,456,001.94       17,107,248.93
公用设施增容费                             221,514.48        1,629,332.04
电子交易网
其他递延支出                             1,686,185.86        2,192,049.56
合计                                     7,052,551.48       43,865,997.87
项    目                                                     剩余摊销期限
装修费                                                                ---
租入固定资产改良支出                                                 84月
技术受让费                                                        24-33月
公用设施增容费                                                       54月
电子交易网                                                        20-22月
其他递延支出                                                          ---
合计
    (十六)短期借款
借款类别                                                          年末数
信用借款                                                 2,288,380,000.00
抵押借款(注)                                              56,360,000.00
保证借款                                                   361,000,000.00
质押借款                                                    21,400,000.00
合              计                                       2,727,140,000.00
借款类别                                                          年初数
信用借款                                                 1,534,000,000.00
抵押借款(注)                                              73,620,000.00
保证借款                                                   449,590,000.00
质押借款                                                              ---
合              计                                       2,057,210,000.00
    注:有关资产抵押情况详见附注十。
    (十七)应付票据
种类                                                      金           额
商业承兑汇票                                               140,931,834.18
银行承兑汇票                                                29,374,371.63
合计                                                       170,306,205.81
    (十八)应付帐款
年末数                                                             年初数
1,702,662,910.86                                         1,567,140,777.91
    年末余额中无欠持本公司5%以上(含5%)表决权股份的股东款项。
    (十九)预收帐款
年末数                                                             年初数
30,472,450.28                                              130,178,673.47
    年末余额中无预收持本公司5%以上(含5%)表决权股份的股东款项。
    (二十)其他应付款:
年末数                                                             年初数
265,550,776.25                                             234,733,143.16
    年末余额中无欠持本公司5%以上(含5%)表决权股份的股东款项。
    (二十一)应付股利
投资者名称                                               年末欠付股利金额
少数股东                                                     6,949,692.65
    (二十二)应交税金
税     种                                                  年    末    数
增值税                                                        -177,087.39
消费税                                                                ---
营业税                                                       3,406,971.49
城建税                                                       4,104,292.73
企业所得税                                                   9,511,339.70
个人所得税                                                  -3,013,327.75
房产税                                                         135,323.98
土地使用税
                                                              -571,672.54
其他
合   计                                                     13,395,840.22
税     种                                                   年   初    数
增值税                                                     -40,464,461.90
消费税                                                                ---
营业税                                                         440,813.92
城建税                                                       1,460,068.75
企业所得税                                                  10,395,276.90
个人所得税                                                  -3,086,102.16
房产税                                                          20,397.98
土地使用税
                                                                29,717.23
其他
合   计                                                    -31,204,289.28
    (二十三)其他应交款
项      目                                                         年末数
教育费附加                                                   5,041,033.91
义务兵优待金                                                    88,717.98
堤防费                                                         848,425.45
河道管理费                                                   1,486,883.23
其他                                                           812,553.96
合   计                                                      8,277,614.53
项      目                                                         年初数
教育费附加                                                   3,763,863.89
义务兵优待金                                                    88,717.98
堤防费                                                         668,396.46
河道管理费                                                   1,249,303.32
其他                                                         2,735,721.17
合   计                                                      8,506,002.82
项      目                                                   年末计缴标准
教育费附加                                                     流转税的3%
义务兵优待金                                                 流转税的0.3%
堤防费                                                         流转税的1%
河道管理费                                               流转税的0.25%-1%
其他                                                     含企业扶持基金等
合   计
    (二十四)预提费用
类   别                                                            年末数
借款利息                                                     4,944,085.94
租赁费                                                       2,340,495.79
咨询费                                                       4,230,745.80
其     他                                                    1,339,194.06
合计                                                        12,854,521.59
类   别                                                            年初数
借款利息                                                     2,931,201.50
租赁费                                                          48,198.91
咨询费                                                                ---
其     他                                                      265,763.13
合计                                                         3,245,163.54
    (二十五)一年内到期的长期借款
借款条件                    年末数                                 年初数
    (二十六)长期借款
借款条件                                                           年末数
信用借款                                                     1,722,500.00
抵押借款(注)                                                 322,304.01
保证借款                                                   108,000,000.00
合计                                                       110,044,804.01
借款条件                                                           年初数
信用借款                                                       400,000.00
抵押借款(注)                                                 400,920.61
保证借款                                                   101,322,500.00
合计                                                       102,123,420.61
    注:有关资产抵押情况详见附注九。
     (二十七)长期应付款
种类                                                               年末数
医药储备资金                                                20,000,000.00
劳动保护措施款                                                        ---
市经委拨款                                                      70,000.00
专项储备资金                                                          ---
商业集团                                                     2,050,000.00
合计                                                        22,120,000.00
种类                                                               年初数
医药储备资金                                                20,000,000.00
劳动保护措施款                                                 150,000.00
市经委拨款                                                      70,000.00
专项储备资金                                                 6,000,000.00
商业集团                                                     2,050,000.00
合计                                                        28,270,000.00
    (二十八)股本
                                         年初数         比例%    本年增加
1、未上市流通股份
(1)发起人股份                  188,248,134.00         39.69
其中:国有股                                ---           ---
国有法人股                       188,248,134.00         39.69
(2)优先股或其他                           ---           ---
其中:转配股                                ---           ---
未上市流通股份合计               188,248,134.00         39.69
2、已上市流通股份
人民币普通股                     286,062,603.00         60.31
已上市流通股份合计               286,062,603.00         60.31
3、股份总数                      474,310,737.00        100.00
                             本年减少                  年末数       比例%
1、未上市流通股份
(1)发起人股份                                188,248,134.00       39.69
其中:国有股                                              ---         ---
国有法人股                                     188,248,134.00       39.69
(2)优先股或其他                                         ---         ---
其中:转配股                                              ---         ---
未上市流通股份合计                             188,248,134.00       39.69
2、已上市流通股份
人民币普通股                                   286,062,603.00       60.31
已上市流通股份合计                             286,062,603.00       60.31
3、股份总数                                    474,310,737.00      100.00
    (二十九)资本公积
项目                                 年初数                      本年增加
股本溢价                     596,641,681.69
股权投资准备                  31,711,260.08                  1,347,014.77
其他资本公积                  44,021,192.95
合计                         673,922,405.95
项目                               本年减少                        年末数
股本溢价                                                   596,641,681.69
股权投资准备                                                33,058,274.85
其他资本公积                                                44,021,192.95
合计                                                       673,721,149.49
    本年度资本公积增加系由于按权益法核算被投资单位的资本公积增加,公司按相应投资比例计入所致。
    (三十)盈余公积
项目                                           年初数            本年增加
法定盈余公积                           128,249,971.84
公益金                                 126,409,525.28
任意盈余公积                            75,213,604.42
合计                                   329,873,101.54
项目                                         本年减少              年末数
法定盈余公积                                               128,249,971.84
公益金                                                     126,409,525.28
任意盈余公积                                                75,213,604.42
合计                                                       329,873,101.54
    (三十一)未分配利润
项  目                                                               金额
调整前年初未分配利润                                       286,730,910.98
调整年初未分配利润(调增为+,调减为-)(注1)
调整后年初未分配利润                                       286,730,910.98
加:本年净利润                                              51,315,602.94
其他转入(注2)
减:提取法定盈余公积
提取法定公益金
提取任意盈余公积
应付普通股股利(注3)
职工奖励基金
转作股本的普通股股利                                                  ---
年末未分配利润                                             338,046,513.92
项  目                                                     提取或分配比例
调整前年初未分配利润
调整年初未分配利润(调增为+,调减为-)(注1)
调整后年初未分配利润
加:本年净利润
其他转入(注2)
减:提取法定盈余公积                                                  10%
提取法定公益金                                                      5-10%
提取任意盈余公积                                                      10%
应付普通股股利(注3)                                                 ---
职工奖励基金                                                           7%
转作股本的普通股股利
年末未分配利润
    (三十二)主营业务收入、主营业务成本
                                                             主营业务收入
项目                                                           本年发生数
1.工业                                                     180,732,947.17
业务2.商业                                               6,583,984,713.01
分部
3.服务业                                                       332,716.40
小计                                                     6,765,050,376.58
公司内各业务分部
相互抵销                                                   698,901,318.61
合计                                                     6,066,149,057.97
上海地区                                                 5,553,777,820.88
安徽地区                                                    93,768,273.48
山东地区                                                   213,326,802.93
浙江地区                                                   888,766,026.56
地区
江西地区
分部
其他地区                                                    15,411,452.73
小计                                                     6,765,050,376.58
公司内各地区分部
相互抵销                                                   698,901,318.61
合计                                                     6,066,149,057.97
                                                             主营业务收入
项目                                                           上年发生数
1.工业                                                     477,867,679.53
业务2.商业                                               5,523,763,995.19
分部
3.服务业
小计                                                     6,001,631,674.72
公司内各业务分部
相互抵销                                                   431,000,000.00
合计                                                     5,570,631,674.72
上海地区                                                 4,855,634,231.19
安徽地区                                                    64,026,415.80
山东地区                                                   195,287,039.41
浙江地区                                                    34,166,441.56
地区
江西地区
分部                                                       397,844,763.00
其他地区                                                    23,672,783.76
小计                                                     5,570,631,674.72
公司内各地区分部
相互抵销
合计                                                     5,570,631,674.72
                                                             主营业务成本
项目                                                           本年发生数
1.工业                                                     143,077,573.56
业务2.商业                                               6,180,392,617.41
分部
3.服务业
小计                                                     6,323,470,190.97
公司内各业务分部
相互抵销                                                   698,901,318.61
合计                                                     5,624,568,872.36
上海地区                                                 5,180,551,791.21
安徽地区                                                    87,460,832.13
山东地区                                                   203,548,640.37
浙江地区                                                   837,614,009.16
地区
江西地区
分部
其他地区                                                    14,294,918.10
小计                                                     6,323,470,190.97
公司内各地区分部
相互抵销                                                   698,901,318.61
合计                                                     5,624,568,872.36
                                                             主营业务成本
项目                                                           上年发生数
1.工业                                                     345,357,795.33
业务2.商业                                               5,145,570,201.75
分部
3.服务业
小计                                                     5,490,927,997.08
公司内各业务分部
相互抵销                                                   431,000,000.00
合计                                                     5,059,927,997.08
上海地区                                                 4,381,399,349.49
安徽地区                                                    58,597,982.97
山东地区                                                   185,944,209.68
浙江地区                                                    32,331,815.78
地区
江西地区
分部                                                       380,581,592.34
其他地区                                                    21,073,046.82
小计                                                     5,059,927,997.08
公司内各地区分部
相互抵销
合计                                                     5,059,927,997.08
                                                             主营业务毛利
项目                                                           本年发生数
1.工业                                                      37,655,373.61
业务2.商业                                                 403,592,095.60
分部
3.服务业                                                       332,716.40
小计                                                       441,580,185.61
公司内各业务分部
相互抵销                                                             0.00
合计                                                       441,580,185.61
上海地区                                                   373,226,029.67
安徽地区                                                     6,307,441.35
山东地区                                                     9,778,162.56
浙江地区                                                    51,152,017.40
地区
江西地区
分部                                                                 0.00
其他地区                                                     1,116,534.63
小计                                                       441,580,185.61
公司内各地区分部
相互抵销                                                             0.00
合计                                                       441,580,185.61
                                                             主营业务毛利
项目                                                           上年发生数
1.工业                                                     132,509,884.20
业务2.商业                                                 378,193,793.44
分部
3.服务业                                                             0.00
小计                                                       510,703,677.64
公司内各业务分部
相互抵销                                                             0.00
合计                                                       510,703,677.64
上海地区                                                   474,234,881.70
安徽地区                                                     5,428,432.83
山东地区                                                     9,342,829.73
浙江地区                                                     1,834,625.78
地区
江西地区
分部                                                        17,263,170.66
其他地区                                                     2,599,736.94
小计                                                       510,703,677.64
公司内各地区分部
相互抵销
合计                                                       510,703,677.64
    公司向前五名客户销售总额为320,251,412.65元,占公司本年全部主营业务收入的5.28%。
    (三十三)主营业务税金及附加:
项        目                                                     计缴标准
营业税                                                       应税收入的5%
消费税                                                                ---
城建税                                                     应交流转税的7%
教育费附加                                                 应交流转税的3%
其他                                                                  ---
合        计
项        目                                                   本年发生数
营业税                                                       1,740,220.20
消费税                                                                ---
城建税                                                       6,053,388.37
教育费附加                                                   3,145,677.79
其他                                                            24,609.29
合        计                                                10,963,895.65
项        目                                                   上年发生数
营业税                                                       1,076,179.72
消费税                                                                ---
城建税                                                       6,820,527.77
教育费附加                                                   3,740,490.10
其他                                                           167,742.48
合        计                                                11,804,940.07
    营业税金及附加本年发生数比上年发生数减少841,044.42元,减少比例为7.12%,减少原因为:本年合并范围缩小所致。
    (三十四)其他业务利润
类           别                              本年发生数
                       收           入    成         本    利          润
劳务收入                  7,939,077.83         3,411.19      7,935,666.64
材料销售                    977,511.38       882,559.00         94,952.38
租赁收入                  4,881,411.00       840,819.11      4,040,591.89
出售无形资产
                         40,000,000.00    12,282,264.69     27,717,735.31
其他                      5,373,909.22       764,175.61      4,609,733.61
合计                     59,171,909.43    14,773,229.60     44,398,679.83
类           别                              上年发生数
                         收         入   成          本     利         润
劳务收入                  7,807,143.93     1,410,911.25      6,396,232.68
材料销售                  9,711,800.05     9,322,535.14        389,264.91
租赁收入                  5,023,226.25     1,108,991.50      3,914,234.75
出售无形资产                       ---
其他                      4,652,678.98       285,430.82      4,367,248.16
合计                     27,194,849.21    12,127,868.71     15,066,980.50
    (三十五)财务费用
类              别                                             本年发生数
利息支出                                                    32,741,053.99
减:利息收入                                                17,053,529.75
汇兑损失                                                       634,182.49
减:汇兑收益
其              他                                         -18,023,864.37
合              计                                          -1,702,157.64
类              别                                             上年发生数
利息支出                                                    18,107,988.13
减:利息收入                                                 8,409,333.23
汇兑损失                                                       855,531.40
减:汇兑收益
其              他                                           1,428,707.79
合              计                                          11,982,894.09
    (三十六)投资收益
    1、本年发生数:
                                             债权投资其他投资收
类        别            股票投资收益
                                                        收益           益
短期投资                                                       318,768.75
长期股权投资
长期债权投资
合计                            0.00                    0.00   318,768.75
                        成本法下确
                                      权益法下确认的股权投资差额股权转让
类        别            认的股权投
                                         股权投资收益                摊销
                            资收益
短期投资
长期股权投资            406,254.40      -7,260,435.93       -1,676,931.35
长期债权投资
合计                    406,254.40      -7,260,435.93       -1,676,931.35
类        别                                 减值准备        合        计
                          处置收益
短期投资                                                       318,768.75
长期股权投资                                                -8,531,112.88
长期债权投资                                                         0.00
合计                          0.00               0.00       -8,212,344.13
    2、上年发生数:
                                                               成本法下确
                                               债权投资
类        别              股票投资收益                         认的股权投
                                                   收益
                                                                   资收益
短期投资                 18,741,405.00                                ---
长期股权投资                  8,175.43              ---        886,254.01
长期债权投资                       ---           165.88               ---
合计                     18,749,580.43           165.88         886254.01
                    权益法下确认的股权投资差额股权转让
类        别
                         股权投资收益             摊销           处置收益
短期投资                          ---              ---                ---
长期股权投资             6,998,255.19      -744,664.01
长期债权投资                      ---              ---                ---
合计                     6,998,255.19      -744,664.01
类        别                 减值准备                        合        计
短期投资                          ---                       18,741,405.00
长期股权投资                                                 7,148,020.62
长期债权投资                      ---                              165.88
合计                                                        25,889,591.49
    3、投资收益汇回无重大限制。
    4、投资收益本年发生数比上年发生数减少34,101,935.62元,减少比例为131.72%,原因为:合并口径差异及短期投资收益较2004年度减少所致。
    (三十七)补贴收入
内容                                                           本年发生数
财政补贴                                                     1,415,200.00
增值税返还                                                     615,806.00
其他                                                           150,000.00
合计                                                         2,181,006.00
内容                                                           上年发生数
财政补贴
增值税返还                                                   3,288,326.02
其他                                                           700,000.00
合计                                                         3,988,326.02
    (三十八)营业外收入
类            别                                               本年发生数
固定资产清理净收益                                          13,703,573.85
固定资产盘盈
赔偿及罚款收入                                                  10,034.10
出售无形资产收益
其        他                                                 1,669,381.29
合        计                                                15,382,989.24
类            别                                               上年发生数
固定资产清理净收益                                          10,039,094.67
固定资产盘盈                                                 1,069,955.58
赔偿及罚款收入                                                  12,150.85
出售无形资产收益                                                      ---
其        他                                                   706,707.75
合        计                                                11,827,908.85
    (三十九)营业外支出
类            别                                               本年发生数
固定资产清理损失                                             1,261,559.95
固定资产盘亏                                                     4,078.40
出售无形资产损失
防洪保安基金                                                   951,581.60
捐赠                                                            35,000.00
罚款及赔偿支出                                               1,506,977.22
其他                                                            20,264.76
合        计                                                 3,779,461.93
类            别                                               上年发生数
固定资产清理损失                                               838,329.92
固定资产盘亏                                                          ---
出售无形资产损失
防洪保安基金
捐赠                                                            27,461.07
罚款及赔偿支出                                                  54,815.55
其他                                                           956,921.49
合        计                                                 1,877,528.03
    六、母公司会计报表主要项目注释:(以下金额单位若未特别注明者均为人民币元,凡未注明年初数的均为年末数)
    (一)应收帐款
    1、帐龄分析
                                   年   末           数
帐龄                                占总额     坏帐准备
                       帐面余额                                  坏帐准备
                                      比例     计提比例
1年以内        1,004,825,635.19     73.06%         0.5%      5,024,128.18
1-2年           167,595,563.88     12.19%          10%     16,759,556.39
2-3年            49,702,732.15      3.61%          20%      9,940,546.43
3年以上          153,241,427.14     11.14%          50%     83,728,041.33
合    计       1,375,365,358.36    100.00%          ---    115,452,272.33
                                   年   初           数
帐龄                                占总额     坏帐准备
                       帐面余额                                  坏帐准备
                                      比例     计提比例
1年以内          823,331,322.77     67.82%         0.5%      4,116,656.61
1-2年           224,005,149.37     18.45%          10%     28,796,143.48
2-3年            39,510,437.06      3.25%          20%      7,902,087.41
3年以上          127,136,880.77     10.48%          50%     77,245,933.85
合    计         1,213,983,7897    100.00%          ---    118,060,821.35
    2、年末应收帐款欠款金额前五名的累计总欠款金额为162,714,375.89元,占应收帐款总金额的11.83%。
    3、除按公司政策对三年以上应收账款按50%计提坏帐准备外,至年末全额计提坏帐准备,或计提坏帐准备比例达到40%及以上的说明:
欠款单位名称                                                     欠款金额
广东瑞翰医药有限公司                                         8,135,134.36
华东医药股份有限公司药品分公司                                 690,649.16
浙江英特药业有限责任公司                                       683,211.54
云南省医疗药品器械公司                                         289,690.28
欠款单位名称                                                     计提比例
广东瑞翰医药有限公司                                                  70%
华东医药股份有限公司药品分公司                                       100%
浙江英特药业有限责任公司                                             100%
云南省医疗药品器械公司                                              100%
欠款单位名称                                                理         由
广东瑞翰医药有限公司                                             涉及诉讼
华东医药股份有限公司药品分公司                   业务员卷款,估计无法收回
浙江英特药业有限责任公司                         业务员卷款,估计无法收回
云南省医疗药品器械公司                         帐龄三年以上,估计无法收回
    4、年末应收帐款中无持本公司5%以上(含5%)表决权股份的股东欠款。
    (二)其他应收款
    1、帐龄分析
                                         年   末   数
帐龄                                  占总额     坏帐准备
                         帐面余额                                坏帐准备
                                     比   例     计提比例
1年以内            845,124,374.77     93.97%        0.50%    4,225,621.87
1-2年              45,678,555.61      5.08%          10%    4,567,855.57
2-3年               4,343,045.93      0.48%          20%      868,609.18
3年以上              4,231,580.62      0.47%          50%    2,814,417.74
合    计           899,377,556.93    100.00%                12,476,504.36
                                     年   初           数
帐龄                                  占总额     坏帐准备
                         帐面余额                                坏帐准备
                                        比例     计提比例
1年以内            730,730,392.76     89.48%        0.50%    3,653,651.96
1-2年              44,450,581.16      5.44%          10%    4,445,058.12
2-3年              30,549,650.04      3.74%          20%   21,642,240.41
3年以上             10,873,260.37      1.34%          50%    7,029,234.22
合    计           816,603,884.33    100.00%          ---   36,770,184.71
    2、年末其他应收款欠款金额前五名的累计总欠款金额为130,533,366.89元,占其他应收款总金额的比例为14.51%。
    3、年末金额较大的其他应收款:
欠款人名称                                                    金       额
中国华源生命产业有限公司                                    68,096,991.19
上海医药(集团)有限公司                                    34,070,000.00
欠款人名称                                                     性质或内容
中国华源生命产业有限公司                                       股权转让款
上海医药(集团)有限公司                                           往来款
    4、年末其他应收款中持本公司5%以上(含5%)表决权股份的股东欠款为34,070,000.00元。
    (三)长期投资
项          目                                      年末数
                                      帐面余额                   减值准备
长期股权投资                  1,270,704,542.51                        ---
项          目                                    年初数
                                      帐面余额                   减值准备
长期股权投资                  1,269,548,442.01                        ---
    1、长期股权投资
    (1)股票投资:
被投资公司名称              股份类别                             股票数量
ST中科                        法人股                                25200
百联股份                      法人股                                33324
小计
                        占被投资公司                               初始投
被投资公司名称
                        注册资本比例                               资成本
ST中科                           <1%                            99,300.00
百联股份                         <1%                            65,450.00
小计                                                           164,750.00
                                帐面
被投资公司名称                                                   减值准备
                                余额
ST中科                     99,300.00                                  ---
百联股份                   65,450.00                                  ---
小计                      164,750.00                                  ---
被投资公司名称                                                   期末市价
ST中科                                                          78,876.00
百联股份                                                       215,939.52
小计                                                           294,815.52
    (2)其他股权投资:
    A、成本法核算的股权投资:
被投资单位名称                                                 投资起止期
上海市长宁区医药有限公司                                        1996-2016
交通银行                                                           无期限
上海药房股份有限公司                                            1997-2017
上海新时代药业股份有限公司                                      2000-2019
上海申银万国证券股份有限公司                                       无期限
长江经济联合发展股份有限公司                                       无期限
上海申威医药有限公司                                            1999-2007
上海医药血液技术产业发展有限公司                                2001-2036
上海云湖医药药材股份有限公司                                       无期限
上海雷允上北区药业有限公司                                         无期限
上海鲲鹏投资发展有限公司                                           无期限
上海复旦张江生物医药股份有限公司                                1999-2023
上海英达莱置业有限公司                                          1989-2009
合计
                                                             占被投资单位
被投资单位名称
                                                             注册资本比例
上海市长宁区医药有限公司                                           15.30%
交通银行                                                              <1%
上海药房股份有限公司                                                8.00%
上海新时代药业股份有限公司                                         20.00%
上海申银万国证券股份有限公司                                          <1%
长江经济联合发展股份有限公司                                          <1%
上海申威医药有限公司                                               30.00%
上海医药血液技术产业发展有限公司                                   10.00%
上海云湖医药药材股份有限公司                                        4.54%
上海雷允上北区药业有限公司                                          5.00%
上海鲲鹏投资发展有限公司                                           10.00%
上海复旦张江生物医药股份有限公司                                   19.66%
上海英达莱置业有限公司                                             14.75%
合计
被投资单位名称                                                   期初余额
上海市长宁区医药有限公司                                       500,000.00
交通银行                                                       288,504.00
上海药房股份有限公司                                         2,920,000.00
上海新时代药业股份有限公司                                   3,000,000.00
上海申银万国证券股份有限公司                                20,000,000.00
长江经济联合发展股份有限公司                                   280,000.00
上海申威医药有限公司                                         1,200,000.00
上海医药血液技术产业发展有限公司                               600,000.00
上海云湖医药药材股份有限公司                                   632,978.00
上海雷允上北区药业有限公司                                   3,002,360.00
上海鲲鹏投资发展有限公司                                     8,263,436.00
上海复旦张江生物医药股份有限公司                            19,147,723.08
上海英达莱置业有限公司                                      29,500,000.00
合计                                                        89,335,001.08
被投资单位名称                                             本期投资增减额
上海市长宁区医药有限公司                                       811,968.20
交通银行                                                              ---
上海药房股份有限公司                                                  ---
上海新时代药业股份有限公司                                            ---
上海申银万国证券股份有限公司                                          ---
长江经济联合发展股份有限公司                                          ---
上海申威医药有限公司                                                  ---
上海医药血液技术产业发展有限公司                                      ---
上海云湖医药药材股份有限公司                                          ---
上海雷允上北区药业有限公司                                            ---
上海鲲鹏投资发展有限公司                                              ---
上海复旦张江生物医药股份有限公司                                      ---
上海英达莱置业有限公司                                                ---
合计                                                           811,968.20
被投资单位名称                                               期末帐面余额
上海市长宁区医药有限公司                                     1,311,968.20
交通银行                                                       288,504.00
上海药房股份有限公司                                         2,920,000.00
上海新时代药业股份有限公司                                   3,000,000.00
上海申银万国证券股份有限公司                                20,000,000.00
长江经济联合发展股份有限公司                                   280,000.00
上海申威医药有限公司                                         1,200,000.00
上海医药血液技术产业发展有限公司                               600,000.00
上海云湖医药药材股份有限公司                                   632,978.00
上海雷允上北区药业有限公司                                   3,002,360.00
上海鲲鹏投资发展有限公司                                     8,263,436.00
上海复旦张江生物医药股份有限公司                            19,147,723.08
上海英达莱置业有限公司                                      29,500,000.00
合计                                                        90,146,969.28
    B、权益法核算的对子公司股权投资:
                                                                     投资
被投资单位名称
                                                                   起止期
上海华氏制药有限公司                                            1999-2048
上海金龟华超医药有限公司                                      1992-无期限
上海华氏大药房有限公司                                          1999-2019
上海华氏资产经营有限公司                                      1998-无期限
上海沪中医药有限公司                                            2000-2020
上海华氏医药高科技实业发展有
限公司                                                          1997-2047
上海福达制药有限公司                                            1996-2016
上海思富医药有限公司                                            1996-2011
上海华仁医药有限公司                                            1996-2016
上海禾丰制药有限公司                                            1993-2013
瑞金药房                                                        1996-2001
上海华氏医药储运有限公司                                      1994-无期限
香港思富有限公司                                                1996-2011
上海市医药股份有限公司安庆公                                        1998-
司                                                                 无期限
上海市医药股份有限公司池州华
氏公司                                                          1998-2028
上海金山医药药材有限公司                                        1997-2017
上海金石医药药材有限公司                                        1997-2017
上海上医新特药商店                                            2000-无期限
上海华因医药有限公司                                            1999-2048
安徽华氏医药有限公司                                            2000-2019
上海华氏经济发展有限公司                                        2001-2017
上海外高桥医药分销中心有限公
司                                                              2001-2021
江西南华医药有限公司                                                2001-
上海制药(苏丹)有限公司                                        1998-2027
上海华嘉医药有限公司                                            2001-2021
上海医药嘉定药业有限公司                                        2002-2010
上海浦东华氏医药有限公司                                        2002-2020
上海市一大药房有限公司                                        2002-无期限
上海健尔药房有限公司                                            2002-2007
上海闵行区药材医药有限公司                                      2002-2020
青岛华氏国风医药有限公司                                        2003-2004
杭州华氏医药有限公司                                            1997-2012
福建华氏康源医药有限公司                                        1998-2018
宁波医药股份有限公司
宁波四明大药房有限公司
上海通用药业股份有限公司
合计
                                                             占被投资单位
被投资单位名称
                                                             注册资本比例
上海华氏制药有限公司                                               90.00%
上海金龟华超医药有限公司                                          100.00%
上海华氏大药房有限公司                                             90.00%
上海华氏资产经营有限公司                                          100.00%
上海沪中医药有限公司                                              100.00%
上海华氏医药高科技实业发展有
限公司                                                            100.00%
上海福达制药有限公司                                               70.00%
上海思富医药有限公司                                               60.00%
上海华仁医药有限公司                                               60.00%
上海禾丰制药有限公司                                               50.00%
瑞金药房                                                          100.00%
上海华氏医药储运有限公司                                           90.00%
香港思富有限公司                                                   99.98%
上海市医药股份有限公司安庆公
司                                                                 60.00%
上海市医药股份有限公司池州华
氏公司                                                             55.00%
上海金山医药药材有限公司                                           51.00%
上海金石医药药材有限公司                                           51.00%
上海上医新特药商店                                                100.00%
上海华因医药有限公司                                              100.00%
安徽华氏医药有限公司                                               67.00%
上海华氏经济发展有限公司                                           90.00%
上海外高桥医药分销中心有限公
司                                                                 65.00%
江西南华医药有限公司                                               50.00%
上海制药(苏丹)有限公司                                           55.00%
上海华嘉医药有限公司                                               40.00%
上海医药嘉定药业有限公司                                           51.00%
上海浦东华氏医药有限公司                                           90.00%
上海市一大药房有限公司                                             50.00%
上海健尔药房有限公司                                               50.00%
上海闵行区药材医药有限公司                                         70.00%
青岛华氏国风医药有限公司                                           65.22%
杭州华氏医药有限公司                                               81.00%
福建华氏康源医药有限公司                                           60.00%
宁波医药股份有限公司                                               51.05%
宁波四明大药房有限公司                                             64.29%
上海通用药业股份有限公司                                           40.00%
合计
被投资单位名称                                                   期初余额
上海华氏制药有限公司                                       107,635,963.72
上海金龟华超医药有限公司                                    11,905,742.06
上海华氏大药房有限公司                                     183,685,511.28
上海华氏资产经营有限公司                                   115,624,434.52
上海沪中医药有限公司                                        42,696,172.97
上海华氏医药高科技实业发展有
限公司                                                       3,406,184.47
上海福达制药有限公司                                        61,063,475.87
上海思富医药有限公司                                        15,933,062.23
上海华仁医药有限公司                                         7,940,735.54
上海禾丰制药有限公司                                        73,592,655.82
瑞金药房                                                     6,060,634.96
上海华氏医药储运有限公司                                     4,563,926.71
香港思富有限公司                                             8,901,801.67
上海市医药股份有限公司安庆公
司                                                           5,574,529.25
上海市医药股份有限公司池州华
氏公司                                                       1,322,281.54
上海金山医药药材有限公司                                     5,510,392.44
上海金石医药药材有限公司                                     1,461,448.91
上海上医新特药商店                                           1,866,106.02
上海华因医药有限公司                                        14,675,329.17
安徽华氏医药有限公司                                         2,310,879.08
上海华氏经济发展有限公司                                     2,636,380.14
上海外高桥医药分销中心有限公
司                                                           7,852,065.75
江西南华医药有限公司                                        93,016,061.78
上海制药(苏丹)有限公司                                    16,322,461.11
上海华嘉医药有限公司                                           937,889.18
上海医药嘉定药业有限公司                                     5,505,907.88
上海浦东华氏医药有限公司                                     4,814,630.21
上海市一大药房有限公司                                       1,143,546.37
上海健尔药房有限公司                                         1,005,079.46
上海闵行区药材医药有限公司                                   9,074,317.92
青岛华氏国风医药有限公司                                    38,867,135.22
杭州华氏医药有限公司                                         9,292,988.95
福建华氏康源医药有限公司                                    18,360,345.10
宁波医药股份有限公司                                        96,236,226.84
宁波四明大药房有限公司                                      21,990,000.00
上海通用药业股份有限公司                                    25,497,374.86
合计                                                     1,028,283,679.00
被投资单位名称
                                                                 本期合计
上海华氏制药有限公司                                        -8,414,283.05
上海金龟华超医药有限公司                                       579,373.62
上海华氏大药房有限公司                                       4,855,895.90
上海华氏资产经营有限公司                                     3,219,044.61
上海沪中医药有限公司                                        10,617,325.15
上海华氏医药高科技实业发展有
限公司                                                          -4,832.72
上海福达制药有限公司                                        -2,745,481.39
上海思富医药有限公司                                          -541,683.54
上海华仁医药有限公司                                           152,609.50
上海禾丰制药有限公司                                        -4,438,258.82
瑞金药房                                                    -1,146,090.45
上海华氏医药储运有限公司                                        16,325.71
香港思富有限公司                                               525,766.28
上海市医药股份有限公司安庆公
司                                                             229,218.11
上海市医药股份有限公司池州华
氏公司                                                          25,257.78
上海金山医药药材有限公司                                        14,683.99
上海金石医药药材有限公司                                        65,392.94
上海上医新特药商店                                           1,167,666.93
上海华因医药有限公司                                        -2,506,023.25
安徽华氏医药有限公司                                            18,536.41
上海华氏经济发展有限公司                                      -610,867.45
上海外高桥医药分销中心有限公
司                                                           1,189,283.45
江西南华医药有限公司                                           751,423.73
上海制药(苏丹)有限公司                                      -117,394.36
上海华嘉医药有限公司                                          -937,889.18
上海医药嘉定药业有限公司                                       147,792.02
上海浦东华氏医药有限公司                                       303,998.09
上海市一大药房有限公司                                          49,422.03
上海健尔药房有限公司                                           270,938.91
上海闵行区药材医药有限公司                                   1,046,563.77
青岛华氏国风医药有限公司                                      -461,633.55
杭州华氏医药有限公司                                          -360,785.30
福建华氏康源医药有限公司                                    -1,218,410.86
宁波医药股份有限公司                                         1,408,143.42
宁波四明大药房有限公司                                         -43,427.21
上海通用药业股份有限公司                                     1,519,824.85
合计                                                         4,627,426.04
被投资单位名称
                                                           其中:投资成本
上海华氏制药有限公司                                                  ---
上海金龟华超医药有限公司                                              ---
上海华氏大药房有限公司                                                ---
上海华氏资产经营有限公司                                              ---
上海沪中医药有限公司                                                  ---
上海华氏医药高科技实业发展有
限公司                                                                ---
上海福达制药有限公司                                                  ---
上海思富医药有限公司                                                  ---
上海华仁医药有限公司                                                  ---
上海禾丰制药有限公司                                                  ---
瑞金药房                                                              ---
上海华氏医药储运有限公司                                              ---
香港思富有限公司                                                      ---
上海市医药股份有限公司安庆公
司                                                                    ---
上海市医药股份有限公司池州华
氏公司                                                                ---
上海金山医药药材有限公司                                              ---
上海金石医药药材有限公司                                              ---
上海上医新特药商店                                                    ---
上海华因医药有限公司                                                  ---
安徽华氏医药有限公司                                                  ---
上海华氏经济发展有限公司                                              ---
上海外高桥医药分销中心有限公
司                                                                    ---
江西南华医药有限公司                                                  ---
上海制药(苏丹)有限公司                                              ---
上海华嘉医药有限公司                                                  ---
上海医药嘉定药业有限公司                                              ---
上海浦东华氏医药有限公司                                              ---
上海市一大药房有限公司                                                ---
上海健尔药房有限公司                                                  ---
上海闵行区药材医药有限公司                                            ---
青岛华氏国风医药有限公司                                              ---
杭州华氏医药有限公司                                                  ---
福建华氏康源医药有限公司                                              ---
宁波医药股份有限公司                                       -46,350,025.99
宁波四明大药房有限公司                                      -7,023,580.37
上海通用药业股份有限公司                                              ---
合计                                                        53,373,606.36
                                                           本期权益增减额
被投资单位名称
                                                                 确认收益
上海华氏制药有限公司                                        -8,414,283.05
上海金龟华超医药有限公司                                       751,479.30
上海华氏大药房有限公司                                       4,864,201.84
上海华氏资产经营有限公司                                     3,219,044.61
上海沪中医药有限公司                                        10,617,325.15
上海华氏医药高科技实业发展有
限公司                                                          -4,832.72
上海福达制药有限公司                                           318,406.73
上海思富医药有限公司                                         1,955,660.21
上海华仁医药有限公司                                           101,827.36
上海禾丰制药有限公司                                         1,565,745.91
瑞金药房                                                     1,576,426.44
上海华氏医药储运有限公司                                        16,325.71
香港思富有限公司                                               525,766.28
上海市医药股份有限公司安庆公
司                                                             229,218.11
上海市医药股份有限公司池州华
氏公司                                                          25,257.78
上海金山医药药材有限公司                                       175,391.83
上海金石医药药材有限公司                                        85,705.25
上海上医新特药商店                                           2,046,646.54
上海华因医药有限公司                                        -2,506,023.25
安徽华氏医药有限公司                                            18,536.41
上海华氏经济发展有限公司                                      -610,867.45
上海外高桥医药分销中心有限公
司                                                           1,708,741.67
江西南华医药有限公司                                           751,423.73
上海制药(苏丹)有限公司                                      -117,394.36
上海华嘉医药有限公司                                          -937,889.18
上海医药嘉定药业有限公司                                       147,792.02
上海浦东华氏医药有限公司                                       303,998.09
上海市一大药房有限公司                                         195,022.03
上海健尔药房有限公司                                           270,938.91
上海闵行区药材医药有限公司                                     295,496.33
青岛华氏国风医药有限公司                                       -41,147.78
杭州华氏医药有限公司                                          -232,983.34
福建华氏康源医药有限公司                                      -945,060.94
宁波医药股份有限公司                                                  ---
宁波四明大药房有限公司                                                ---
上海通用药业股份有限公司                                     1,519,824.85
合计                                                        19,475,721.00
被投资单位名称
                                                                 差额摊销
上海华氏制药有限公司                                                  ---
上海金龟华超医药有限公司                                              ---
上海华氏大药房有限公司                                           8,305.95
上海华氏资产经营有限公司                                              ---
上海沪中医药有限公司                                                  ---
上海华氏医药高科技实业发展有
限公司                                                                ---
上海福达制药有限公司                                            63,888.12
上海思富医药有限公司                                           -22,656.25
上海华仁医药有限公司                                           -50,782.14
上海禾丰制药有限公司                                                  ---
瑞金药房                                                              ---
上海华氏医药储运有限公司                                              ---
香港思富有限公司                                                      ---
上海市医药股份有限公司安庆公
司                                                                    ---
上海市医药股份有限公司池州华
氏公司                                                                ---
上海金山医药药材有限公司                                              ---
上海金石医药药材有限公司                                              ---
上海上医新特药商店                                                    ---
上海华因医药有限公司                                                  ---
安徽华氏医药有限公司                                                  ---
上海华氏经济发展有限公司                                              ---
上海外高桥医药分销中心有限公
司                                                                    ---
江西南华医药有限公司                                                  ---
上海制药(苏丹)有限公司                                              ---
上海华嘉医药有限公司                                                  ---
上海医药嘉定药业有限公司                                              ---
上海浦东华氏医药有限公司                                              ---
上海市一大药房有限公司                                                ---
上海健尔药房有限公司                                                  ---
上海闵行区药材医药有限公司                                      75,000.00
青岛华氏国风医药有限公司                                              ---
杭州华氏医药有限公司                                                  ---
福建华氏康源医药有限公司                                              ---
宁波医药股份有限公司                                                  ---
宁波四明大药房有限公司                                                ---
上海通用药业股份有限公司                                              ---
合计                                                            73,755.68
被投资单位名称
                                                                 分得利润
上海华氏制药有限公司                                                  ---
上海金龟华超医药有限公司                                       172,105.68
上海华氏大药房有限公司                                                ---
上海华氏资产经营有限公司                                              ---
上海沪中医药有限公司                                                  ---
上海华氏医药高科技实业发展有
限公司                                                                ---
上海福达制药有限公司                                         3,000,000.00
上海思富医药有限公司                                         2,520,000.00
上海华仁医药有限公司                                                    -
上海禾丰制药有限公司                                         6,000,000.00
瑞金药房                                                     2,722,516.89
上海华氏医药储运有限公司                                              ---
香港思富有限公司                                                      ---
上海市医药股份有限公司安庆公
司                                                                    ---
上海市医药股份有限公司池州华
氏公司                                                                ---
上海金山医药药材有限公司                                       160,707.84
上海金石医药药材有限公司                                        95,027.31
上海上医新特药商店                                             878,979.61
上海华因医药有限公司                                                  ---
安徽华氏医药有限公司                                                  ---
上海华氏经济发展有限公司                                              ---
上海外高桥医药分销中心有限公
司                                                             519,458.22
江西南华医药有限公司                                                  ---
上海制药(苏丹)有限公司                                              ---
上海华嘉医药有限公司                                                  ---
上海医药嘉定药业有限公司                                              ---
上海浦东华氏医药有限公司                                              ---
上海市一大药房有限公司                                         145,600.00
上海健尔药房有限公司                                                  ---
上海闵行区药材医药有限公司                                     450,237.06
青岛华氏国风医药有限公司                                              ---
杭州华氏医药有限公司                                                  ---
福建华氏康源医药有限公司                                              ---
宁波医药股份有限公司                                                  ---
宁波四明大药房有限公司                                                ---
上海通用药业股份有限公司                                              ---
合计                                                        16,664,632.61
被投资单位名称
                                                                 初始投资
上海华氏制药有限公司                                        26,643,125.64
上海金龟华超医药有限公司                                     3,000,000.00
上海华氏大药房有限公司                                      10,000,000.00
上海华氏资产经营有限公司                                    20,000,000.00
上海沪中医药有限公司                                        10,000,000.00
上海华氏医药高科技实业发展有
限公司                                                       5,000,000.00
上海福达制药有限公司                                        15,890,000.00
上海思富医药有限公司                                         7,200,000.00
上海华仁医药有限公司                                        15,000,000.00
上海禾丰制药有限公司                                        10,371,242.60
瑞金药房                                                       300,000.00
上海华氏医药储运有限公司                                     5,000,000.00
香港思富有限公司                                             6,000,000.00
上海市医药股份有限公司安庆公
司                                                           3,180,000.00
上海市医药股份有限公司池州华
氏公司                                                         467,500.00
上海金山医药药材有限公司                                     5,100,000.00
上海金石医药药材有限公司                                     1,020,000.00
上海上医新特药商店                                          16,947,250.00
上海华因医药有限公司                                         4,900,000.00
安徽华氏医药有限公司                                         2,150,000.00
上海华氏经济发展有限公司                                     4,500,000.00
上海外高桥医药分销中心有限公
司                                                           6,500,000.00
江西南华医药有限公司                                        90,000,000.00
上海制药(苏丹)有限公司                                     9,043,016.00
上海华嘉医药有限公司                                         2,000,000.00
上海医药嘉定药业有限公司                                     5,100,000.00
上海浦东华氏医药有限公司                                     4,500,000.00
上海市一大药房有限公司                                         550,000.00
上海健尔药房有限公司                                           500,000.00
上海闵行区药材医药有限公司                                   6,500,000.00
青岛华氏国风医药有限公司                                    38,000,000.00
杭州华氏医药有限公司                                        10,833,800.00
福建华氏康源医药有限公司                                    19,196,100.00
宁波医药股份有限公司                                        96,236,226.84
宁波四明大药房有限公司                                      21,990,000.00
上海通用药业股份有限公司                                    16,000,000.00
合计                                                       499,618,261.08
                                                                 期末余额
被投资单位名称
                                                                 累计增减
上海华氏制药有限公司                                        72,578,555.03
上海金龟华超医药有限公司                                     9,485,115.68
上海华氏大药房有限公司                                     178,541,407.18
上海华氏资产经营有限公司                                    98,843,479.13
上海沪中医药有限公司                                        43,313,498.12
上海华氏医药高科技实业发展有
限公司                                                      -1,598,648.25
上海福达制药有限公司                                        42,427,994.48
上海思富医药有限公司                                         8,191,378.69
上海华仁医药有限公司                                        -6,906,654.96
上海禾丰制药有限公司                                        58,783,154.40
瑞金药房                                                     4,614,544.51
上海华氏医药储运有限公司                                      -419,747.58
香港思富有限公司                                             3,427,567.95
上海市医药股份有限公司安庆公
司                                                           2,623,747.36
上海市医药股份有限公司池州华
氏公司                                                         880,039.32
上海金山医药药材有限公司                                       425,076.43
上海金石医药药材有限公司                                       506,841.85
上海上医新特药商店                                         -13,913,477.05
上海华因医药有限公司                                         7,269,305.92
安徽华氏医药有限公司                                           179,415.49
上海华氏经济发展有限公司                                    -2,474,487.31
上海外高桥医药分销中心有限公
司                                                           2,541,349.20
江西南华医药有限公司                                         3,767,485.51
上海制药(苏丹)有限公司                                     7,162,050.75
上海华嘉医药有限公司                                        -2,000,000.00
上海医药嘉定药业有限公司                                       553,699.90
上海浦东华氏医药有限公司                                       618,628.30
上海市一大药房有限公司                                         642,968.40
上海健尔药房有限公司                                           776,018.37
上海闵行区药材医药有限公司                                   3,620,881.69
青岛华氏国风医药有限公司                                       405,501.67
杭州华氏医药有限公司                                        -1,901,596.35
福建华氏康源医药有限公司                                    -2,054,165.76
宁波医药股份有限公司                                         1,408,143.42
宁波四明大药房有限公司                                         -43,427.21
上海通用药业股份有限公司                                    11,017,199.71
合计                                                       533,292,843.96
被投资单位名称
                                                                     合计
上海华氏制药有限公司                                        99,221,680.67
上海金龟华超医药有限公司                                    12,485,115.68
上海华氏大药房有限公司                                     188,541,407.18
上海华氏资产经营有限公司                                   118,843,479.13
上海沪中医药有限公司                                        53,313,498.12
上海华氏医药高科技实业发展有
限公司                                                       3,401,351.75
上海福达制药有限公司                                        58,317,994.48
上海思富医药有限公司                                        15,391,378.69
上海华仁医药有限公司                                         8,093,345.04
上海禾丰制药有限公司                                        69,154,397.00
瑞金药房                                                     4,914,544.51
上海华氏医药储运有限公司                                     4,580,252.42
香港思富有限公司                                             9,427,567.95
上海市医药股份有限公司安庆公
司                                                           5,803,747.36
上海市医药股份有限公司池州华
氏公司                                                       1,347,539.32
上海金山医药药材有限公司                                     5,525,076.43
上海金石医药药材有限公司                                     1,526,841.85
上海上医新特药商店                                           3,033,772.95
上海华因医药有限公司                                        12,169,305.92
安徽华氏医药有限公司                                         2,329,415.49
上海华氏经济发展有限公司                                     2,025,512.69
上海外高桥医药分销中心有限公
司                                                           9,041,349.20
江西南华医药有限公司                                        93,767,485.51
上海制药(苏丹)有限公司                                    16,205,066.75
上海华嘉医药有限公司                                                -0.00
上海医药嘉定药业有限公司                                     5,653,699.90
上海浦东华氏医药有限公司                                     5,118,628.30
上海市一大药房有限公司                                       1,192,968.40
上海健尔药房有限公司                                         1,276,018.37
上海闵行区药材医药有限公司                                  10,120,881.69
青岛华氏国风医药有限公司                                    38,405,501.67
杭州华氏医药有限公司                                         8,932,203.65
福建华氏康源医药有限公司                                    17,141,934.24
宁波医药股份有限公司                                        97,644,370.26
宁波四明大药房有限公司                                      21,946,572.79
上海通用药业股份有限公司                                    27,017,199.71
合计                                                     1,032,911,105.05
    C、权益法核算的对联营企业股权投资:
                                                                     投资
被投资单位名称
                                                                   起止期
重庆医药上海药品销
售有限公司                                                      1999-2006
上海医药商务网络有
限公司                                                          1999-2019
吉林亚泰华氏医药有
限公司                                                          2001-2020
上海华天广告有限公
司                                                              1990-2010
上海华源长富药业
(集团)有限公司                                                1992-2029
上海先导药业有限公
司                                                                 无期限
上海绿苑药房有限公
司                                                              2000-2010
上海华翔药业有限公
司                                                              2003-2023
上海麦卡森医药有限
公司                                                            2003-2053
上海医药物流中心有
限公司
合计
                                                             占被投资单位
被投资单位名称
                                                             注册资本比例
重庆医药上海药品销
售有限公司                                                         49.00%
上海医药商务网络有
限公司                                                             26.25%
吉林亚泰华氏医药有
限公司                                                             48.00%
上海华天广告有限公
司                                                                 40.00%
上海华源长富药业
(集团)有限公司                                                   24.13%
上海先导药业有限公
司                                                                 24.00%
上海绿苑药房有限公
司                                                                 30.00%
上海华翔药业有限公
司                                                                 27.00%
上海麦卡森医药有限
公司                                                               35.00%
上海医药物流中心有
限公司                                                             28.57%
合计
被投资单位名称                                                   期初余额
重庆医药上海药品销
售有限公司                                                   1,772,928.31
上海医药商务网络有
限公司                                                         107,247.64
吉林亚泰华氏医药有
限公司                                                       5,400,661.07
上海华天广告有限公
司                                                             873,767.30
上海华源长富药业
(集团)有限公司                                           128,256,835.00
上海先导药业有限公
司                                                           2,647,672.46
上海绿苑药房有限公
司                                                             876,802.62
上海华翔药业有限公
司                                                           1,375,282.61
上海麦卡森医药有限
公司                                                         1,856,089.50
上海医药物流中心有
限公司                                                                ---
合计                                                       143,167,286.51
被投资单位名称
                                                                 本期合计
重庆医药上海药品销
售有限公司                                                     139,983.05
上海医药商务网络有
限公司                                                         -76,405.08
吉林亚泰华氏医药有
限公司                                                         -10,986.48
上海华天广告有限公
司                                                               1,677.03
上海华源长富药业
(集团)有限公司                                             2,079,163.22
上海先导药业有限公
司                                                                    ---
上海绿苑药房有限公
司                                                             215,494.22
上海华翔药业有限公
司                                                                    ---
上海麦卡森医药有限
公司                                                           -34,494.29
上海医药物流中心有
限公司                                                       2,000,000.00
合计                                                         4,314,431.67
被投资单位名称
                                                           其中:投资成本
重庆医药上海药品销
售有限公司                                                            ---
上海医药商务网络有
限公司                                                                ---
吉林亚泰华氏医药有
限公司                                                                ---
上海华天广告有限公
司                                                                    ---
上海华源长富药业
(集团)有限公司                                                      ---
上海先导药业有限公
司                                                                    ---
上海绿苑药房有限公
司                                                                    ---
上海华翔药业有限公
司                                                                    ---
上海麦卡森医药有限
公司                                                                  ---
上海医药物流中心有
限公司                                                       2,000,000.00
合计                                                         2,000,000.00
                                                           本期权益增减额
被投资单位名称
                                                                 确认收益
重庆医药上海药品销
售有限公司                                                     139,983.05
上海医药商务网络有
限公司                                                         -76,405.08
吉林亚泰华氏医药有
限公司                                                         211,661.28
上海华天广告有限公
司                                                               1,677.03
上海华源长富药业
(集团)有限公司                                             2,079,163.22
上海先导药业有限公
司                                                                    ---
上海绿苑药房有限公
司                                                             275,494.22
上海华翔药业有限公
司                                                                    ---
上海麦卡森医药有限
公司                                                            50,377.31
上海医药物流中心有
限公司                                                                ---
合计                                                         2,681,951.03
被投资单位名称
                                                                 差额摊销
重庆医药上海药品销
售有限公司                                                            ---
上海医药商务网络有
限公司                                                                ---
吉林亚泰华氏医药有
限公司                                                                ---
上海华天广告有限公
司                                                                    ---
上海华源长富药业
(集团)有限公司                                                      ---
上海先导药业有限公
司                                                                    ---
上海绿苑药房有限公
司                                                                    ---
上海华翔药业有限公
司                                                                    ---
上海麦卡森医药有限
公司                                                                  ---
上海医药物流中心有
限公司                                                                ---
合计                                                                  ---
被投资单位名称
                                                                 分得利润
重庆医药上海药品销
售有限公司                                                            ---
上海医药商务网络有
限公司                                                                ---
吉林亚泰华氏医药有
限公司                                                                ---
上海华天广告有限公
司                                                                    ---
上海华源长富药业
(集团)有限公司                                                      ---
上海先导药业有限公
司                                                                    ---
上海绿苑药房有限公
司                                                                    ---
上海华翔药业有限公
司                                                                    ---
上海麦卡森医药有限
公司                                                                  ---
上海医药物流中心有
限公司                                                                ---
合计                                                                  ---
被投资单位名称
                                                                 初始投资
重庆医药上海药品销
售有限公司                                                     980,000.00
上海医药商务网络有
限公司                                                       5,250,000.00
吉林亚泰华氏医药有
限公司                                                       4,800,000.00
上海华天广告有限公
司                                                             912,000.00
上海华源长富药业
(集团)有限公司                                            77,616,942.78
上海先导药业有限公
司                                                           3,600,000.00
上海绿苑药房有限公
司                                                             150,000.00
上海华翔药业有限公
司                                                           1,350,000.00
上海麦卡森医药有限
公司                                                         1,750,000.00
上海医药物流中心有
限公司                                                       2,000,000.00
合计                                                        98,408,942.78
                                                                 期末余额
被投资单位名称
                                                                 累计增减
重庆医药上海药品销
售有限公司                                                     932,911.36
上海医药商务网络有
限公司                                                      -5,219,157.44
吉林亚泰华氏医药有
限公司                                                         589,674.59
上海华天广告有限公
司                                                             -36,555.67
上海华源长富药业
(集团)有限公司                                            52,719,055.44
上海先导药业有限公
司                                                            -952,327.54
上海绿苑药房有限公
司                                                             942,296.84
上海华翔药业有限公
司                                                              25,282.61
上海麦卡森医药有限
公司                                                            71,595.21
上海医药物流中心有
限公司                                                                ---
合计                                                        49,072,775.40
被投资单位名称
                                                                     合计
重庆医药上海药品销
售有限公司                                                   1,912,911.36
上海医药商务网络有
限公司                                                          30,842.56
吉林亚泰华氏医药有
限公司                                                       5,389,674.59
上海华天广告有限公
司                                                             875,444.33
上海华源长富药业
(集团)有限公司                                           130,335,998.22
上海先导药业有限公
司                                                           2,647,672.46
上海绿苑药房有限公
司                                                           1,092,296.84
上海华翔药业有限公
司                                                           1,375,282.61
上海麦卡森医药有限
公司                                                         1,821,595.21
上海医药物流中心有
限公司                                                       2,000,000.00
合计                                                       147,481,718.18
    D、其中:股权投资差额:
被投资单位名称                                                   初始金额
上海华氏大药房有限公司                                         166,118.93
上海福达制药有限公司                                         1,022,209.82
上海思富医药有限公司                                          -679,687.30
上海华仁医药有限公司                                        -1,523,464.21
上海闵行区药材医药有限公司                                   3,000,000.00
青岛华氏国风医药有限公司                                     9,059,689.03
杭州华氏医药有限公司                                         3,834,058.75
福建华氏康源医药有限公司                                    10,933,996.88
宁波医药股份有限公司                                        46,350,025.99
宁波四明大药房有限公司                                       7,023,580.37
小计                                                        79,186,528.26
被投资单位名称                                                   形成原因
上海华氏大药房有限公司                                           溢价投入
上海福达制药有限公司                                                  ---
上海思富医药有限公司                                                  ---
上海华仁医药有限公司                                                  ---
上海闵行区药材医药有限公司                                       溢价收购
青岛华氏国风医药有限公司                                         溢价收购
杭州华氏医药有限公司                                             溢价收购
福建华氏康源医药有限公司                                         溢价收购
宁波医药股份有限公司                                             溢价收购
宁波四明大药房有限公司                                           溢价收购
小计                                                             溢价收购
被投资单位名称                                                   摊销期限
上海华氏大药房有限公司                                               10年
上海福达制药有限公司                                                  8年
上海思富医药有限公司                                                 15年
上海华仁医药有限公司                                                 15年
上海闵行区药材医药有限公司                                           20年
青岛华氏国风医药有限公司                                             20年
杭州华氏医药有限公司                                                 15年
福建华氏康源医药有限公司                                             20年
宁波医药股份有限公司                                                 50年
宁波四明大药房有限公司                                               50年
小计
被投资单位名称                                                 本期摊销额
上海华氏大药房有限公司                                           8,305.95
上海福达制药有限公司                                            63,888.12
上海思富医药有限公司                                           -22,656.25
上海华仁医药有限公司                                           -50,782.14
上海闵行区药材医药有限公司                                      75,000.00
青岛华氏国风医药有限公司                                       226,492.23
杭州华氏医药有限公司                                           127,801.96
福建华氏康源医药有限公司                                       273,349.92
宁波医药股份有限公司                                           463,500.26
宁波四明大药房有限公司                                          70,235.80
小计                                                         1,235,135.84
被投资单位名称                                                   本期转出
上海华氏大药房有限公司                                                ---
上海福达制药有限公司                                                  ---
上海思富医药有限公司                                                  ---
上海华仁医药有限公司                                                  ---
上海闵行区药材医药有限公司                                            ---
青岛华氏国风医药有限公司                                              ---
杭州华氏医药有限公司                                                  ---
福建华氏康源医药有限公司                                              ---
宁波医药股份有限公司                                                  ---
宁波四明大药房有限公司                                                ---
小计                                                                  ---
被投资单位名称                                                   摊余金额
上海华氏大药房有限公司                                         141,201.10
上海福达制药有限公司                                           447,216.79
上海思富医药有限公司                                          -362,499.88
上海华仁医药有限公司                                          -812,514.24
上海闵行区药材医药有限公司                                   2,625,000.00
青岛华氏国风医药有限公司                                     8,380,212.36
杭州华氏医药有限公司                                         3,450,652.87
福建华氏康源医药有限公司                                    10,113,947.12
宁波医药股份有限公司                                        45,886,525.73
宁波四明大药房有限公司                                       6,953,344.57
小计                                                        76,823,086.41
    (四)主营业务收入及主营业务成本:
                                                             主营业务收入
项目                                 本年发生数                上年发生数
工业                                                                  ---
商业                           3,125,808,107.90          2,884,454,837.88
服务业                                                                ---
公司内各业务分部相互抵销
合计                            3,125,808,107.9          2,884,454,837.88
                                        主营业务毛利
项目                                      本年发生数           上年发生数
工业                                                                  ---
商业                                2,991,594,183.40     2,749,850,400.56
服务业                                                                ---
公司内各业务分部相互抵销
合计                                 2,991,594,183.4     2,749,850,400.56
                                  主营业务成本
项目                                上年发生数                 本年发生数
工业                                                                  ---
商业                            134,213,924.50             134,604,437.32
服务业                                                                ---
公司内各业务分部相互抵销                                              ---
合计                            134,213,924.50             134,604,437.32
    (五)投资收益:
    1、本年发生数:
类别                     股票投资收益    债权投资收益      成本法下确认的
                                                             股权投资收益
短期投资
长期股权投资
                                                               350,000.00
长期债权投资
合计
                                 0.00            0.00          350,000.00
类别                              权益法下确认的                 股权投资
                                    股权投资收益                 差额摊销
短期投资
长期股权投资
                                   13,739,578.75            -1,235,135.84
长期债权投资
合计
                                   13,739,578.75            -1,235,135.84
类别                                 股权转让                    减值准备
                                     收    益
短期投资
长期股权投资
长期债权投资
合计
                                         0.00                        0.00
类别                                                                 合计
短期投资
                                                                     0.00
长期股权投资
                                                            12,854,442.91
长期债权投资
                                                                     0.00
合计
                                                            12,854,442.91
    2、上年发生数:
类别                     股票投资收益     债权投资收益     成本法下确认的
                                                             股权投资收益
短期投资
                        14,000,000.00              ---                ---
长期股权投资
                             3,998.88              ---             575000
长期债权投资
                                  ---           165.88                ---
合计
                        14,003,998.88           165.88         575,000.00
类别                   权益法下确认的         股权投资           股权转让
                         股权投资收益         差额摊销           收    益
短期投资
                                ---               ---                 ---
长期股权投资
                        32010946.07        -744664.01                 ---
长期债权投资
                                ---               ---                 ---
合计
                      32,010,946.07       -744,664.01                0.00
类别                     减值准备                                 合   计
短期投资
                              ---                           14,000,000.00
长期股权投资
                                                            31,845,280.94
长期债权投资
                              ---                                  165.88
合计
                             0.00                           45,845,446.82
    3、投资收益汇回无重大限制。
    七、关联方关系及其交易:
    (一)存在控制关系的关联方情况:
    1、存在控制关系的关联方:
    (1)控制本公司的关联方:
企业名称                                                         注册地址
上海医药(集团)有限公司                                      太仓路200号
企业名称                                                     与本企业关系
上海医药(集团)有限公司                                       控股母公司
企业名称                                                       法定代表人
上海医药(集团)有限公司                                           周玉成
    (2)受本公司控制的关联方:详见附注四。
    2、存在控制关系的关联方的注册资本及其变化(单位:万元)
企业名称                                                           年初数
上海医药(集团)有限公司                                       315,872.00
上海华氏医药高科技实业发展有限公司                                 500.00
上海瑞金药房                                                       100.00
上海华氏医药储运有限公司                                           500.00
香港思富有限公司                                                   600.00
上海市医药股份有限公司安庆公司                                     450.00
上海天平实业公司                                                    50.00
上海天平制药厂保健食品分厂                                          35.10
上海青平药业有限公司                                               600.00
上海市医药股份有限公司池州华氏公司                                  85.00
上海金山医药药材有限公司                                         1,000.00
上海金石医药药材有限公司                                           200.00
安徽华氏医药有限公司                                               321.00
上海华氏大药房有限公司                                           9,000.00
上海华氏杨浦大药房有限公司                                         100.00
上海华氏武夷大药房有限公司                                         100.00
上海华氏大药房配送中心有限公司                                     500.00
安徽省六安华氏大药房有限公司                                       150.00
上海华氏制药有限公司                                            12,559.29
上海华氏资产经营有限公司                                        11,000.00
上海福达制药有限公司                                             2,880.56
上海思富医药有限公司                                             1,200.00
上海华仁医药有限公司                                             2,000.00
上海大东化学试剂供应站                                              10.22
上海华臣商场有限公司                                               200.07
上海华氏西部大药房有限公司                                         500.00
上海金龟华超医药有限公司                                           300.00
上海禾丰制药有限公司                                          USD1,000.00
上海市医药股份有限公司黄山华氏有限公司                             300.00
上海沪中医药有限公司                                             1,000.00
上海上医新特药商店                                                  60.00
上海华天广告有限公司                                               100.00
上海华氏经济发展有限公司                                           500.00
贵州华氏大药房延安连锁有限公司                                   1,000.00
江西南华医药有限公司                                            18,000.00
江西黄庆仁栈华氏大药房有限公司                                   1,000.00
江西华康药业有限公司                                               202.00
上海外高桥医药分销中心有限公司                                   1,000.00
上海制药(苏丹)有限公司                                        USD220.00
上海浦东华氏医药有限公司                                           500.00
上海闵行药材医药有限公司                                           800.00
上海医药嘉定药业有限公司                                         1,000.00
上海市一大药房有限公司                                             110.00
上海健尔药房有限公司                                               100.00
上海华因医药有限公司                                             1,000.00
上海华嘉医药有限公司                                               500.00
宁波亚太生物技术有限公司                                         4,378.80
嘉兴华氏大药房兰台零售连锁有限公司                                 900.00
上海华氏虹口大药房有限公司                                         100.00
上海华氏全新大药房有限公司                                         100.00
南通华氏康乐大药房有限公司                                       1,200.00
上海罗达医药有限公司                                               500.00
青岛华氏国风医药有限公司                                         4,600.00
杭州华氏医药有限公司                                             1,281.86
福建华氏康源医药有限公司                                         1,000.00
宁波医药股份有限公司                                             5,797.77
宁波四明大药房有限公司                                           2,380.00
上海通用药业股份有限公司                                         4,000.00
企业名称                                                 本年增加本年减少
上海医药(集团)有限公司                                              ---
上海华氏医药高科技实业发展有限公司                                    ---
上海瑞金药房                                                          ---
上海华氏医药储运有限公司                                              ---
香港思富有限公司                                                      ---
上海市医药股份有限公司安庆公司                                        ---
上海天平实业公司                                                      ---
上海天平制药厂保健食品分厂                                            ---
上海青平药业有限公司                                                  ---
上海市医药股份有限公司池州华氏公司                                    ---
上海金山医药药材有限公司                                              ---
上海金石医药药材有限公司                                              ---
安徽华氏医药有限公司                                                  ---
上海华氏大药房有限公司                                                ---
上海华氏杨浦大药房有限公司                                            ---
上海华氏武夷大药房有限公司                                            ---
上海华氏大药房配送中心有限公司                                        ---
安徽省六安华氏大药房有限公司                                          ---
上海华氏制药有限公司                                                  ---
上海华氏资产经营有限公司                                              ---
上海福达制药有限公司                                                  ---
上海思富医药有限公司                                                  ---
上海华仁医药有限公司                                                  ---
上海大东化学试剂供应站                                                ---
上海华臣商场有限公司                                                  ---
上海华氏西部大药房有限公司                                            ---
上海金龟华超医药有限公司                                              ---
上海禾丰制药有限公司                                                  ---
上海市医药股份有限公司黄山华氏有限公司                                ---
上海沪中医药有限公司                                                  ---
上海上医新特药商店                                                    ---
上海华天广告有限公司                                                  ---
上海华氏经济发展有限公司                                              ---
贵州华氏大药房延安连锁有限公司                                        ---
江西南华医药有限公司                                                  ---
江西黄庆仁栈华氏大药房有限公司                                        ---
江西华康药业有限公司                                                  ---
上海外高桥医药分销中心有限公司                                        ---
上海制药(苏丹)有限公司                                              ---
上海浦东华氏医药有限公司                                              ---
上海闵行药材医药有限公司                                              ---
上海医药嘉定药业有限公司                                              ---
上海市一大药房有限公司                                                ---
上海健尔药房有限公司                                                  ---
上海华因医药有限公司                                                  ---
上海华嘉医药有限公司                                                  ---
宁波亚太生物技术有限公司                                              ---
嘉兴华氏大药房兰台零售连锁有限公司                                    ---
上海华氏虹口大药房有限公司                                            ---
上海华氏全新大药房有限公司                                            ---
南通华氏康乐大药房有限公司                                            ---
上海罗达医药有限公司                                                  ---
青岛华氏国风医药有限公司                                              ---
杭州华氏医药有限公司                                                  ---
福建华氏康源医药有限公司                                              ---
宁波医药股份有限公司                                                  ---
宁波四明大药房有限公司                                                ---
上海通用药业股份有限公司                                              ---
企业名称
上海医药(集团)有限公司                                              ---
上海华氏医药高科技实业发展有限公司                                    ---
上海瑞金药房                                                          ---
上海华氏医药储运有限公司                                              ---
香港思富有限公司                                                      ---
上海市医药股份有限公司安庆公司                                        ---
上海天平实业公司                                                      ---
上海天平制药厂保健食品分厂                                            ---
上海青平药业有限公司                                                  ---
上海市医药股份有限公司池州华氏公司                                    ---
上海金山医药药材有限公司                                              ---
上海金石医药药材有限公司                                              ---
安徽华氏医药有限公司                                                  ---
上海华氏大药房有限公司                                                ---
上海华氏杨浦大药房有限公司                                            ---
上海华氏武夷大药房有限公司                                            ---
上海华氏大药房配送中心有限公司                                        ---
安徽省六安华氏大药房有限公司                                          ---
上海华氏制药有限公司                                                  ---
上海华氏资产经营有限公司                                              ---
上海福达制药有限公司                                                  ---
上海思富医药有限公司                                                  ---
上海华仁医药有限公司                                                  ---
上海大东化学试剂供应站                                                ---
上海华臣商场有限公司                                                  ---
上海华氏西部大药房有限公司                                            ---
上海金龟华超医药有限公司                                              ---
上海禾丰制药有限公司                                                  ---
上海市医药股份有限公司黄山华氏有限公司                                ---
上海沪中医药有限公司                                                  ---
上海上医新特药商店                                                    ---
上海华天广告有限公司                                                  ---
上海华氏经济发展有限公司                                              ---
贵州华氏大药房延安连锁有限公司                                        ---
江西南华医药有限公司                                                  ---
江西黄庆仁栈华氏大药房有限公司                                        ---
江西华康药业有限公司                                                  ---
上海外高桥医药分销中心有限公司                                        ---
上海制药(苏丹)有限公司                                              ---
上海浦东华氏医药有限公司                                              ---
上海闵行药材医药有限公司                                              ---
上海医药嘉定药业有限公司                                              ---
上海市一大药房有限公司                                                ---
上海健尔药房有限公司                                                  ---
上海华因医药有限公司                                                  ---
上海华嘉医药有限公司                                                  ---
宁波亚太生物技术有限公司                                              ---
嘉兴华氏大药房兰台零售连锁有限公司                                    ---
上海华氏虹口大药房有限公司                                            ---
上海华氏全新大药房有限公司                                            ---
南通华氏康乐大药房有限公司                                            ---
上海罗达医药有限公司                                                  ---
青岛华氏国风医药有限公司                                              ---
杭州华氏医药有限公司                                                  ---
福建华氏康源医药有限公司                                              ---
宁波医药股份有限公司                                                  ---
宁波四明大药房有限公司                                                ---
上海通用药业股份有限公司                                              ---
企业名称                                                           年末数
上海医药(集团)有限公司                                       315,872.00
上海华氏医药高科技实业发展有限公司                                 500.00
上海瑞金药房                                                       100.00
上海华氏医药储运有限公司                                           500.00
香港思富有限公司                                                   600.00
上海市医药股份有限公司安庆公司                                     450.00
上海天平实业公司                                                    50.00
上海天平制药厂保健食品分厂                                          35.10
上海青平药业有限公司                                               600.00
上海市医药股份有限公司池州华氏公司                                  85.00
上海金山医药药材有限公司                                         1,000.00
上海金石医药药材有限公司                                           200.00
安徽华氏医药有限公司                                               321.00
上海华氏大药房有限公司                                           9,000.00
上海华氏杨浦大药房有限公司